

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 December 2002 (12.12.2002)

PCT

(10) International Publication Number
WO 02/099043 A2

(51) International Patent Classification⁷: C12N

(US). ENGST, Stefan [DE/US]; 555 Buena Vista West,
#702, San Francisco, CA 94117 (US).

(21) International Application Number: PCT/US02/17319

(74) Agents: BRUNELLE, Jan et al.; Exelixis, Inc., P.O. Box
511, 170 Harbor Way, South San Francisco, CA 94083-
0511 (US).

(22) International Filing Date: 3 June 2002 (03.06.2002)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) Priority Data:
60/296,080 5 June 2001 (05.06.2001) US
60/328,509 10 October 2001 (10.10.2001) US

(71) Applicant (*for all designated States except US*): EXELIS,
INC. [US/US]; P.O. Box 511, 170 Harbor Way, South San
Francisco, CA 94083-0511 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): FRIEDMAN, Lori
[US/US]; One Bayside Village Place, Unit 212, San
Francisco, CA 94107 (US). PLOWMAN, Gregory, D.
[US/US]; 35 Winding Way, San Carlos, CA 94070 (US).
BELVIN, Marcia [US/US]; 921 Santa Fe Avenue, Albany,
CA 94706 (US). FRANCIS-LANG, Helen [GB/US];
1782 Pacific Avenue, Apt. 2, San Francisco, CA 94109
(US). LI, Danxi [CN/US]; 90 Behr Avenue, #302, San
Francisco, CA 94131 (US). FUNKE, Roel, P. [NL/US];
343 California Avenue, South San Francisco, CA 94080

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/099043 A2

(54) Title: P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE

(57) Abstract: Human P5CR genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of P5CR are provided.

P5CRs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE**REFERENCE TO RELATED APPLICATIONS**

This application claims priority to U.S. provisional patent applications 60/296,080
5 filed June 5, 2001, and 60/328,509, filed October 10, 2001. The contents of the prior
applications are hereby incorporated in their entirety.

BACKGROUND OF THE INVENTION

The p53 gene is mutated in over 50 different types of human cancers, including
10 familial and spontaneous cancers, and is believed to be the most commonly mutated gene
in human cancer (Zambetti and Levine, FASEB (1993) 7:855-865; Hollstein, *et al.*,
Nucleic Acids Res. (1994) 22:3551-3555). Greater than 90% of mutations in the p53 gene
are missense mutations that alter a single amino acid that inactivates p53 function.
Aberrant forms of human p53 are associated with poor prognosis, more aggressive tumors,
15 metastasis, and short survival rates (Mitsudomi *et al.*, Clin Cancer Res 2000 Oct;
6(10):4055-63; Koshland, Science (1993) 262:1953).

The human p53 protein normally functions as a central integrator of signals including
DNA damage, hypoxia, nucleotide deprivation, and oncogene activation (Prives, Cell
(1998) 95:5-8). In response to these signals, p53 protein levels are greatly increased with
20 the result that the accumulated p53 activates cell cycle arrest or apoptosis depending on
the nature and strength of these signals. Indeed, multiple lines of experimental evidence
have pointed to a key role for p53 as a tumor suppressor (Levine, Cell (1997) 88:323-331).
For example, homozygous p53 "knockout" mice are developmentally normal but exhibit
nearly 100% incidence of neoplasia in the first year of life (Donehower *et al.*, Nature
25 (1992) 356:215-221).

The biochemical mechanisms and pathways through which p53 functions in normal
and cancerous cells are not fully understood, but one clearly important aspect of p53
function is its activity as a gene-specific transcriptional activator. Among the genes with
known p53-response elements are several with well-characterized roles in either regulation
30 of the cell cycle or apoptosis, including GADD45, p21/Waf1/Cip1, cyclin G, Bax, IGF-
BP3, and MDM2 (Levine, Cell (1997) 88:323-331).

Pyrroline 5 carboxylate reductase (P5CR) catalyzes the NAD(P)H-dependent
conversion of Pyrroline 5 carboxylate (P5C) to proline. Proline is itself oxidized to P5C

by proline oxidase (PUT1) in mitochondria. P5C is further oxidized in mitochondria by P5C dehydrogenase (PUT2) to glutamate.

Accumulation of P5C is implicated in p53-dependent initiation of apoptosis. Proline oxidase is up-regulated in carcinoma cell lines challenged with a p53-expressing
5 adenovirus, leading to apoptosis of the cells. Moreover, cell-permeable conjugates of P5C alone induce apoptosis (Maxwell and Davis 2000 Proc Natl Acad Sci U S A 97:13009-14). To date, however, a direct genetic relationship between p53 and P5CR has not been established. P5CR is overexpressed in tumors of the colon, liver, and lung (Herzfeld A, et al., 1978 Cancer 42:1280-1283; Herzfeld A, et al., 1980 Cancer 45:2383-2388; Herzfeld
10 A, and Greengard O. 1980 Cancer 46:2047-2054; Notetman DA et al. (2001) Cancer Res 61:3124-3130).

DNA and protein sequences for P5CR have been identified in a wide variety of organisms, including the yeast (DNA Genbank Identifier number (GI#) M57886; protein: GI# AAA34905), arabidopsis (DNA GI#977548; protein GI# CAC01879), *Drosophila*
15 (DNA GI#5733737; protein GI#5733740), mouse (DNA GI#13879493; protein GI#13879494); and human (DNA GI#s189497 and 10435995; Protein GI#s 189498 and 10435996), among others.

The ability to manipulate the genomes of model organisms such as *Drosophila* and provides a powerful means to analyze biochemical processes that, due to significant
20 evolutionary conservation, has direct relevance to more complex vertebrate organisms. Due to a high level of gene and pathway conservation, the strong similarity of cellular processes, and the functional conservation of genes between these model organisms and mammals, identification of the involvement of novel genes in particular pathways and their functions in such model organisms can directly contribute to the understanding of the
25 correlative pathways and methods of modulating them in mammals (see, for example, Mechler BM et al., 1985 EMBO J 4:1551-1557; Gateff E. 1982 Adv. Cancer Res. 37: 33-74; Watson KL., et al., 1994 J Cell Sci. 18: 19-33; Miklos GL, and Rubin GM. 1996 Cell 86:521-529; Wassarman DA, et al., 1995 Curr Opin Gen Dev 5: 44-50; and Booth DR. 1999 Cancer Metastasis Rev. 18: 261-284). For example, a genetic screen can be carried
30 out in an invertebrate model organism having underexpression (e.g. knockout) or overexpression of a gene (referred to as a "genetic entry point") that yields a visible phenotype. Additional genes are mutated in a random or targeted manner. When a gene mutation changes the original phenotype caused by the mutation in the genetic entry point, the gene is identified as a "modifier" involved in the same or overlapping pathway as the

genetic entry point. When the genetic entry point is an ortholog of a human gene implicated in a disease pathway, such as p53, modifier genes can be identified that may be attractive candidate targets for novel therapeutics.

All references cited herein, including sequence information in referenced Genbank
5 identifier numbers and website references, are incorporated herein in their entireties.

SUMMARY OF THE INVENTION

We have discovered genes that modify the p53 pathway in *Drosophila*, and identified their human orthologs, hereinafter referred to as P5CR. The invention provides methods
10 for utilizing these p53 modifier genes and polypeptides to identify candidate therapeutic agents that can be used in the treatment of disorders associated with defective p53 function. Preferred P5CR-modulating agents specifically bind to P5CR polypeptides and restore p53 function. Other preferred P5CR-modulating agents are nucleic acid
modulators such as antisense oligomers and RNAi that repress P5CR gene expression or
15 product activity by, for example, binding to and inhibiting the respective nucleic acid (i.e. DNA or mRNA).

P5CR-specific modulating agents may be evaluated by any convenient *in vitro* or *in vivo* assay for molecular interaction with a P5CR polypeptide or nucleic acid. In one
embodiment, candidate p53 modulating agents are tested with an assay system comprising
20 a P5CR polypeptide or nucleic acid. Candidate agents that produce a change in the activity of the assay system relative to controls are identified as candidate p53 modulating agents. The assay system may be cell-based or cell-free. P5CR-modulating agents include P5CR related proteins (e.g. dominant negative mutants, and biotherapeutics); P5CR-specific antibodies; P5CR-specific antisense oligomers and other nucleic acid
25 modulators; and chemical agents that specifically bind P5CR or compete with P5CR binding target. In one specific embodiment, a small molecule modulator is identified using an enzymatic assay. In specific embodiments, the screening assay system is selected from an apoptosis assay, a cell proliferation assay, an angiogenesis assay, and a hypoxic induction assay.

30 In another embodiment, candidate p53 pathway modulating agents are further tested using a second assay system that detects changes in the p53 pathway, such as angiogenic, apoptotic, or cell proliferation changes produced by the originally identified candidate agent or an agent derived from the original agent. The second assay system may use cultured cells or non-human animals. In specific embodiments, the secondary assay

system uses non-human animals, including animals predetermined to have a disease or disorder implicating the p53 pathway, such as an angiogenic, apoptotic, or cell proliferation disorder (e.g. cancer).

The invention further provides methods for modulating the p53 pathway in a mammalian cell by contacting the mammalian cell with an agent that specifically binds a P5CR polypeptide or nucleic acid. The agent may be a small molecule modulator, a nucleic acid modulator, or an antibody and may be administered to a mammalian animal predetermined to have a pathology associated the p53 pathway.

10 DETAILED DESCRIPTION OF THE INVENTION

Genetic modifier screens were designed to identify modifiers of the p53 pathway in *Drosophila* where p53 was overexpressed in the wing (Ollmann M, et al., Cell 2000 101: 91-101). The *Drosophila* P5CR gene was identified as a modifier of the p53 pathway. Accordingly, vertebrate orthologs of these modifiers, and preferably the human orthologs, P5CR genes (i.e., nucleic acids and polypeptides) are attractive drug targets for the treatment of pathologies associated with a defective p53 signaling pathway, such as cancer.

In vitro and in vivo methods of assessing P5CR function are provided herein. Modulation of the P5CR or their respective binding partners is useful for understanding the association of the p53 pathway and its members in normal and disease conditions and for developing diagnostics and therapeutic modalities for p53 related pathologies. P5CR-modulating agents that act by inhibiting or enhancing P5CR expression, directly or indirectly, for example, by affecting a P5CR function such as enzymatic (e.g., catalytic) or binding activity, can be identified using methods provided herein. Inhibiting P5CR function may induce apoptosis or enhance activity of apoptosis-inducing agents. Thus, P5CR modulating agents are useful in diagnosis, therapy and pharmaceutical development.

Nucleic acids and polypeptides of the invention

Sequences related to P5CR nucleic acids and polypeptides that can be used in the invention are disclosed in Genbank (referenced by Genbank identifier (GI) number), as GI#s 189497 (SEQ ID NO:1), 10435995 (SEQ ID NO:2), 16306657 (SEQ ID NO:3), 18391546 (SEQ ID NO:4), 14124939 (SEQ ID NO:7), 18089015 (SEQ ID NO:8), and 4960117 (SEQ ID NO:9) for nucleic acid, and GI#s 189498 (SEQ ID NO:10), 10435996

(SEQ ID NO:11), 5902036 (SEQ ID NO:12), 12751493 (SEQ ID NO:13), and 7019479 (SEQ ID NO:14) for polypeptides.

P5CRs are reductase proteins with P5CR domains. The term "P5CR polypeptide" refers to a full-length P5CR protein or a functionally active fragment or derivative thereof.

- 5 A "functionally active" P5CR fragment or derivative exhibits one or more functional activities associated with a full-length, wild-type P5CR protein, such as antigenic or immunogenic activity, enzymatic activity, ability to bind natural cellular substrates, etc. The functional activity of P5CR proteins, derivatives and fragments can be assayed by various methods known to one skilled in the art (Current Protocols in Protein Science
- 10 (1998) Coligan *et al.*, eds., John Wiley & Sons, Inc., Somerset, New Jersey) and as further discussed below. For purposes herein, functionally active fragments also include those fragments that comprise one or more structural domains of a P5CR, such as a reductase domain or a binding domain. Protein domains can be identified using the PFAM program (Bateman A., *et al.*, Nucleic Acids Res, 1999, 27:260-2; <http://pfam.wustl.edu>). For
- 15 example, P5CR domain of SEQ ID NO:10 is located at amino acids 1-253 (PFAM 01089). Methods for obtaining P5CR polypeptides are also further described below. In some embodiments, preferred fragments are functionally active, domain-containing fragments comprising at least 25 contiguous amino acids, preferably at least 50, more preferably 75, and most preferably at least 100 contiguous amino acids of any one of SEQ ID NOs:10,
- 20 11, 12, 13, or 14 (a P5CR). In further preferred embodiments, the fragment comprises the entire reductase (functionally active) domain.

- The term "P5CR nucleic acid" refers to a DNA or RNA molecule that encodes a P5CR polypeptide. Preferably, the P5CR polypeptide or nucleic acid or fragment thereof is from a human, but can also be an ortholog, or derivative thereof with at least 70% sequence
- 25 identity, preferably at least 80%, more preferably 85%, still more preferably 90%, and most preferably at least 95% sequence identity with P5CR. As used herein, "percent (%) sequence identity" with respect to a subject sequence, or a specified portion of a subject sequence, is defined as the percentage of nucleotides or amino acids in the candidate derivative sequence identical with the nucleotides or amino acids in the subject sequence
- 30 (or specified portion thereof), after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent sequence identity, as generated by the program WU-BLAST-2.0a19 (Altschul *et al.*, J. Mol. Biol. (1997) 215:403-410; <http://blast.wustl.edu/blast/README.html>) with all the search parameters set to default values. The HSP S and HSP S2 parameters are dynamic values and are established by the

program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched. A % identity value is determined by the number of matching identical nucleotides or amino acids divided by the sequence length for which the percent identity is being reported.

- 5 "Percent (%) amino acid sequence similarity" is determined by doing the same calculation as for determining % amino acid sequence identity, but including conservative amino acid substitutions in addition to identical amino acids in the computation.

- A conservative amino acid substitution is one in which an amino acid is substituted for another amino acid having similar properties such that the folding or activity of the protein is not significantly affected. Aromatic amino acids that can be substituted for each other are phenylalanine, tryptophan, and tyrosine; interchangeable hydrophobic amino acids are leucine, isoleucine, methionine, and valine; interchangeable polar amino acids are glutamine and asparagine; interchangeable basic amino acids are arginine, lysine and histidine; interchangeable acidic amino acids are aspartic acid and glutamic acid; and interchangeable small amino acids are alanine, serine, threonine, cysteine and glycine.

- Alternatively, an alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman (Smith and Waterman, 1981, *Advances in Applied Mathematics* 2:482-489; database: European Bioinformatics Institute <http://www.ebi.ac.uk/MPsrch/>; Smith and Waterman, 1981, *J. of Molec. Biol.*, 147:195-197; Nicholas et al., 1998, "A Tutorial on Searching Sequence Databases and Sequence Scoring Methods" (www.psc.edu) and references cited therein.; W.R. Pearson, 1991, *Genomics* 11:635-650). This algorithm can be applied to amino acid sequences by using the scoring matrix developed by Dayhoff (Dayhoff: *Atlas of Protein Sequences and Structure*, M. O. Dayhoff ed., 5 suppl. 3:353-358, National Biomedical Research Foundation, Washington, D.C., USA), and normalized by Gribskov (Gribskov 1986 *Nucl. Acids Res.* 14(6):6745-6763). The Smith-Waterman algorithm may be employed where default parameters are used for scoring (for example, gap open penalty of 12, gap extension penalty of two). From the data generated, the "Match" value reflects "sequence identity."

- 30 Derivative nucleic acid molecules of the subject nucleic acid molecules include sequences that hybridize to the nucleic acid sequence of SEQ ID NOs:1, 2, 3, 4, 5, 6, 7, 8, or 9. The stringency of hybridization can be controlled by temperature, ionic strength, pH, and the presence of denaturing agents such as formamide during hybridization and washing. Conditions routinely used are set out in readily available procedure texts (*e.g.*,

Current Protocol in Molecular Biology, Vol. 1, Chap. 2.10, John Wiley & Sons, Publishers (1994); Sambrook *et al.*, Molecular Cloning, Cold Spring Harbor (1989)). In some embodiments, a nucleic acid molecule of the invention is capable of hybridizing to a nucleic acid molecule containing the nucleotide sequence of any one of SEQ ID NOs:1, 2, 3, 4, 5, 6, 7, 8, or 9 under stringent hybridization conditions that comprise: prehybridization of filters containing nucleic acid for 8 hours to overnight at 65° C in a solution comprising 6X single strength citrate (SSC) (1X SSC is 0.15 M NaCl, 0.015 M Na citrate; pH 7.0), 5X Denhardt's solution, 0.05% sodium pyrophosphate and 100 µg/ml herring sperm DNA; hybridization for 18-20 hours at 65° C in a solution containing 6X SSC, 1X Denhardt's solution, 100 µg/ml yeast tRNA and 0.05% sodium pyrophosphate; and washing of filters at 65° C for 1h in a solution containing 0.2X SSC and 0.1% SDS (sodium dodecyl sulfate).

In other embodiments, moderately stringent hybridization conditions are used that comprise: pretreatment of filters containing nucleic acid for 6 h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA; hybridization for 18-20h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 µg/ml salmon sperm DNA, and 10% (wt/vol) dextran sulfate; followed by washing twice for 1 hour at 55° C in a solution containing 2X SSC and 0.1% SDS.

Alternatively, low stringency conditions can be used that comprise: incubation for 8 hours to overnight at 37° C in a solution comprising 20% formamide, 5 x SSC, 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured sheared salmon sperm DNA; hybridization in the same buffer for 18 to 20 hours; and washing of filters in 1 x SSC at about 37° C for 1 hour.

Isolation, Production, Expression, and Mis-expression of P5CR Nucleic Acids and Polypeptides

P5CR nucleic acids and polypeptides, useful for identifying and testing agents that modulate P5CR function and for other applications related to the involvement of P5CR in the p53 pathway. P5CR nucleic acids and derivatives and orthologs thereof may be obtained using any available method. For instance, techniques for isolating cDNA or genomic DNA sequences of interest by screening DNA libraries or by using polymerase chain reaction (PCR) are well known in the art. In general, the particular use for the

protein will dictate the particulars of expression, production, and purification methods. For instance, production of proteins for use in screening for modulating agents may require methods that preserve specific biological activities of these proteins, whereas production of proteins for antibody generation may require structural integrity of particular epitopes. Expression of proteins to be purified for screening or antibody production may require the addition of specific tags (*e.g.*, generation of fusion proteins). Overexpression of a P5CR protein for assays used to assess P5CR function, such as involvement in cell cycle regulation or hypoxic response, may require expression in eukaryotic cell lines capable of these cellular activities. Techniques for the expression, production, and purification of proteins are well known in the art; any suitable means therefore may be used (*e.g.*, Higgins SJ and Hames BD (eds.) *Protein Expression: A Practical Approach*, Oxford University Press Inc., New York 1999; Stanbury PF et al., *Principles of Fermentation Technology*, 2nd edition, Elsevier Science, New York, 1995; Doonan S (ed.) *Protein Purification Protocols*, Humana Press, New Jersey, 1996; Coligan JE et al, *Current Protocols in Protein Science* (eds.), 1999, John Wiley & Sons, New York). In particular embodiments, recombinant P5CR is expressed in a cell line known to have defective p53 function (*e.g.* SAOS-2 osteoblasts, H1299 lung cancer cells, C33A and HT3 cervical cancer cells, HT-29 and DLD-1 colon cancer cells, among others, available from American Type Culture Collection (ATCC), Manassas, VA). The recombinant cells are used in cell-based screening assay systems of the invention, as described further below.

The nucleotide sequence encoding a P5CR polypeptide can be inserted into any appropriate expression vector. The necessary transcriptional and translational signals, including promoter/enhancer element, can derive from the native P5CR gene and/or its flanking regions or can be heterologous. A variety of host-vector expression systems may be utilized, such as mammalian cell systems infected with virus (*e.g.* vaccinia virus, adenovirus, *etc.*); insect cell systems infected with virus (*e.g.* baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, plasmid, or cosmid DNA. A host cell strain that modulates the expression of, modifies, and/or specifically processes the gene product may be used.

To detect expression of the P5CR gene product, the expression vector can comprise a promoter operably linked to a P5CR gene nucleic acid, one or more origins of replication, and, one or more selectable markers (*e.g.* thymidine kinase activity, resistance to antibiotics, *etc.*). Alternatively, recombinant expression vectors can be identified by

assaying for the expression of the P5CR gene product based on the physical or functional properties of the P5CR protein in *in vitro* assay systems (*e.g.* immunoassays).

5 The P5CR protein, fragment, or derivative may be optionally expressed as a fusion, or chimeric protein product (i.e. it is joined via a peptide bond to a heterologous protein sequence of a different protein), for example to facilitate purification or detection. A chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other using standard methods and expressing the chimeric product. A chimeric product may also be made by protein synthetic techniques, *e.g.* by use of a peptide synthesizer (Hunkapiller *et al.*, Nature (1984) 310:105-111).

10 Once a recombinant cell that expresses the P5CR gene sequence is identified, the gene product can be isolated and purified using standard methods (*e.g.* ion exchange, affinity, and gel exclusion chromatography; centrifugation; differential solubility; electrophoresis, cite purification reference). Alternatively, native P5CR proteins can be purified from natural sources, by standard methods (*e.g.* immunoaffinity purification). Once a protein is
15 obtained, it may be quantified and its activity measured by appropriate methods, such as immunoassay, bioassay, or other measurements of physical properties, such as crystallography.

The methods of this invention may also use cells that have been engineered for altered expression (mis-expression) of P5CR or other genes associated with the p53 pathway. As
20 used herein, mis-expression encompasses ectopic expression, over-expression, under-expression, and non-expression (*e.g.* by gene knock-out or blocking expression that would otherwise normally occur).

Genetically modified animals

Animal models that have been genetically modified to alter P5CR expression may be
25 used in *in vivo* assays to test for activity of a candidate p53 modulating agent, or to further assess the role of P5CR in a p53 pathway process such as apoptosis or cell proliferation. Preferably, the altered P5CR expression results in a detectable phenotype, such as decreased or increased levels of cell proliferation, angiogenesis, or apoptosis compared to control animals having normal P5CR expression. The genetically modified animal may
30 additionally have altered p53 expression (*e.g.* p53 knockout). Preferred genetically modified animals are mammals such as primates, rodents (preferably mice), cows, horses, goats, sheep, pigs, dogs and cats. Preferred non-mammalian species include zebrafish, *C. elegans*, and *Drosophila*. Preferred genetically modified animals are transgenic animals

having a heterologous nucleic acid sequence present as an extrachromosomal element in a portion of its cells, i.e. mosaic animals (see, for example, techniques described by Jakobovits, 1994, *Curr. Biol.* 4:761-763.) or stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells). Heterologous nucleic acid is introduced into the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells of the host animal.

Methods of making transgenic animals are well-known in the art (for transgenic mice see Brinster et al., *Proc. Nat. Acad. Sci. USA* 82: 4438-4442 (1985), U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al., and Hogan, B., *Manipulating the Mouse Embryo*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1986); for particle bombardment see U.S. Pat. No., 4,945,050, by Sandford *et al.*; for transgenic *Drosophila* see Rubin and Spradling, *Science* (1982) 218:348-53 and U.S. Pat. No. 4,670,388; for transgenic insects see Berghammer A.J. *et al.*, A Universal Marker for Transgenic Insects (1999) *Nature* 402:370-371; for transgenic Zebrafish see Lin S., *Transgenic Zebrafish*, *Methods Mol Biol.* (2000);136:375-3830); for microinjection procedures for fish, amphibian eggs and birds see Houdebine and Chourrout, *Experientia* (1991) 47:897-905; for transgenic rats see Hammer *et al.*, *Cell* (1990) 63:1099-1112; and for culturing of embryonic stem (ES) cells and the subsequent production of transgenic animals by the introduction of DNA into ES cells using methods such as electroporation, calcium phosphate/DNA precipitation and direct injection see, e.g., *Teratocarcinomas and Embryonic Stem Cells, A Practical Approach*, E. J. Robertson, ed., IRL Press (1987)). Clones of the nonhuman transgenic animals can be produced according to available methods (see Wilmut, I. *et al.* (1997) *Nature* 385:810-813; and PCT International Publication Nos. WO 97/07668 and WO 97/07669).

In one embodiment, the transgenic animal is a "knock-out" animal having a heterozygous or homozygous alteration in the sequence of an endogenous P5CR gene that results in a decrease of P5CR function, preferably such that P5CR expression is undetectable or insignificant. Knock-out animals are typically generated by homologous recombination with a vector comprising a transgene having at least a portion of the gene to be knocked out. Typically a deletion, addition or substitution has been introduced into the transgene to functionally disrupt it. The transgene can be a human gene (e.g., from a human genomic clone) but more preferably is an ortholog of the human gene derived from the transgenic host species. For example, a mouse P5CR gene is used to construct a homologous recombination vector suitable for altering an endogenous P5CR gene in the

mouse genome. Detailed methodologies for homologous recombination in mice are available (see Capecchi, Science (1989) 244:1288-1292; Joyner *et al.*, Nature (1989) 338:153-156). Procedures for the production of non-rodent transgenic mammals and other animals are also available (Houdebine and Chourrout, *supra*; Pursel *et al.*, Science (1989) 244:1281-1288; Simms *et al.*, Bio/Technology (1988) 6:179-183). In a preferred embodiment, knock-out animals, such as mice harboring a knockout of a specific gene, may be used to produce antibodies against the human counterpart of the gene that has been knocked out (Claesson MH *et al.*, (1994) Scan J Immunol 40:257-264; Declerck PJ *et al.*, (1995) J Biol Chem. 270:8397-400).

10 In another embodiment, the transgenic animal is a "knock-in" animal having an alteration in its genome that results in altered expression (e.g., increased (including ectopic) or decreased expression) of the P5CR gene, e.g., by introduction of additional copies of P5CR, or by operatively inserting a regulatory sequence that provides for altered expression of an endogenous copy of the P5CR gene. Such regulatory sequences include
15 inducible, tissue-specific, and constitutive promoters and enhancer elements. The knock-in can be homozygous or heterozygous.

Transgenic nonhuman animals can also be produced that contain selected systems allowing for regulated expression of the transgene. One example of such a system that may be produced is the cre/loxP recombinase system of bacteriophage P1 (Lakso *et al.*,
20 PNAS (1992) 89:6232-6236; U.S. Pat. No. 4,959,317). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other
25 containing a transgene encoding a recombinase. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman *et al.* (1991) Science 251:1351-1355; U.S. Pat. No. 5,654,182). In a preferred embodiment, both Cre-LoxP and Flp-Frt are used in the same system to regulate expression of the transgene, and for sequential deletion of vector sequences in the same cell (Sun X *et al.*
30 (2000) Nat Genet 25:83-6).

The genetically modified animals can be used in genetic studies to further elucidate the p53 pathway, as animal models of disease and disorders implicating defective p53 function, and for *in vivo* testing of candidate therapeutic agents, such as those identified in screens described below. The candidate therapeutic agents are administered to a

genetically modified animal having altered P5CR function and phenotypic changes are compared with appropriate control animals such as genetically modified animals that receive placebo treatment, and/or animals with unaltered P5CR expression that receive candidate therapeutic agent.

- 5 In addition to the above-described genetically modified animals having altered P5CR function, animal models having defective p53 function (and otherwise normal P5CR function), can be used in the methods of the present invention. For example, a p53 knockout mouse can be used to assess, *in vivo*, the activity of a candidate p53 modulating agent identified in one of the *in vitro* assays described below. p53 knockout mice are
10 described in the literature (Jacks et al., Nature 2001;410:1111-1116, 1043-1044; Donehower *et al.*, supra). Preferably, the candidate p53 modulating agent when administered to a model system with cells defective in p53 function, produces a detectable phenotypic change in the model system indicating that the p53 function is restored, i.e., the cells exhibit normal cell cycle progression.

15

Modulating Agents

- The invention provides methods to identify agents that interact with and/or modulate the function of P5CR and/or the p53 pathway. Such agents are useful in a variety of diagnostic and therapeutic applications associated with the p53 pathway, as well as in
20 further analysis of the P5CR protein and its contribution to the p53 pathway. Accordingly, the invention also provides methods for modulating the p53 pathway comprising the step of specifically modulating P5CR activity by administering a P5CR-interacting or -modulating agent.

- In a preferred embodiment, P5CR-modulating agents inhibit or enhance P5CR activity
25 or otherwise affect normal P5CR function, including transcription, protein expression, protein localization, and cellular or extra-cellular activity. In a further preferred embodiment, the candidate p53 pathway- modulating agent specifically modulates the function of the P5CR. The phrases "specific modulating agent", "specifically modulates", etc., are used herein to refer to modulating agents that directly bind to the P5CR
30 polypeptide or nucleic acid, and preferably inhibit, enhance, or otherwise alter, the function of the P5CR. The term also encompasses modulating agents that alter the interaction of the P5CR with a binding partner or substrate (e.g. by binding to a binding partner of a P5CR, or to a protein/binding partner complex, and inhibiting function).

Preferred P5CR-modulating agents include small molecule compounds; P5CR-interacting proteins; and nucleic acid modulators such as antisense and RNA inhibitors. The modulating agents may be formulated in pharmaceutical compositions, for example, as compositions that may comprise other active ingredients, as in combination therapy, and/or suitable carriers or excipients. Techniques for formulation and administration of the compounds may be found in "Remington's Pharmaceutical Sciences" Mack Publishing Co., Easton, PA, 19th edition.

Small molecule modulators

Small molecules, are often preferred to modulate function of proteins with enzymatic function, and/or containing protein interaction domains. Chemical agents, referred to in the art as "small molecule" compounds are typically organic, non-peptide molecules, having a molecular weight less than 10,000, preferably less than 5,000, more preferably less than 1,000, and most preferably less than 500. This class of modulators includes chemically synthesized molecules, for instance, compounds from combinatorial chemical libraries. Synthetic compounds may be rationally designed or identified based on known or inferred properties of the P5CR protein or may be identified by screening compound libraries. Alternative appropriate modulators of this class are natural products, particularly secondary metabolites from organisms such as plants or fungi, which can also be identified by screening compound libraries for P5CR-modulating activity. Methods for generating and obtaining compounds are well known in the art (Schreiber SL, Science (2000) 151: 1964-1969; Radmann J and Gunther J, Science (2000) 151:1947-1948).

Small molecule modulators identified from screening assays, as described below, can be used as lead compounds from which candidate clinical compounds may be designed, optimized, and synthesized. Such clinical compounds may have utility in treating pathologies associated with the p53 pathway. The activity of candidate small molecule modulating agents may be improved several-fold through iterative secondary functional validation, as further described below, structure determination, and candidate modulator modification and testing. Additionally, candidate clinical compounds are generated with specific regard to clinical and pharmacological properties. For example, the reagents may be derivatized and re-screened using *in vitro* and *in vivo* assays to optimize activity and minimize toxicity for pharmaceutical development.

Protein Modulators

Specific P5CR-interacting proteins are useful in a variety of diagnostic and therapeutic applications related to the p53 pathway and related disorders, as well as in validation assays for other P5CR-modulating agents. In a preferred embodiment, P5CR-interacting proteins affect normal P5CR function, including transcription, protein expression, protein localization, and cellular or extra-cellular activity. In another embodiment, P5CR-interacting proteins are useful in detecting and providing information about the function of P5CR proteins, as is relevant to p53 related disorders, such as cancer (e.g., for diagnostic means).

10 A P5CR-interacting protein may be endogenous, i.e. one that naturally interacts genetically or biochemically with a P5CR, such as a member of the P5CR pathway that modulates P5CR expression, localization, and/or activity. P5CR-modulators include dominant negative forms of P5CR-interacting proteins and of P5CR proteins themselves. Yeast two-hybrid and variant screens offer preferred methods for identifying endogenous P5CR-interacting proteins (Finley, R. L. et al. (1996) in DNA Cloning-Expression Systems: A Practical Approach, eds. Glover D. & Hames B. D (Oxford University Press, Oxford, England), pp. 169-203; Fashema SF et al., Gene (2000) 250:1-14; Drees BL Curr Opin Chem Biol (1999) 3:64-70; Vidal M and Legrain P Nucleic Acids Res (1999) 27:919-29; and U.S. Pat. No. 5,928,868). Mass spectrometry is an alternative preferred method for the elucidation of protein complexes (reviewed in, e.g., Pandley A and Mann M, Nature (2000) 405:837-846; Yates JR 3rd, Trends Genet (2000) 16:5-8).

20 A P5CR-interacting protein may be an exogenous protein, such as a P5CR-specific antibody or a T-cell antigen receptor (see, e.g., Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory; Harlow and Lane (1999) Using antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press). P5CR antibodies are further discussed below.

In preferred embodiments, a P5CR-interacting protein specifically binds a P5CR protein. In alternative preferred embodiments, a P5CR-modulating agent binds a P5CR substrate, binding partner, or cofactor.

30

Antibodies

In another embodiment, the protein modulator is a P5CR specific antibody agonist or antagonist. The antibodies have therapeutic and diagnostic utilities, and can be used in screening assays to identify P5CR modulators. The antibodies can also be used in

dissecting the portions of the P5CR pathway responsible for various cellular responses and in the general processing and maturation of the P5CR.

Antibodies that specifically bind P5CR polypeptides can be generated using known methods. Preferably the antibody is specific to a mammalian ortholog of P5CR polypeptide, and more preferably, to human P5CR. Antibodies may be polyclonal, monoclonal (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, fragments produced by a FAb expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Epitopes of P5CR which are particularly antigenic can be selected, for example, by routine screening of P5CR polypeptides for antigenicity or by applying a theoretical method for selecting antigenic regions of a protein (Hopp and Wood (1981), Proc. Nati. Acad. Sci. U.S.A. 78:3824-28; Hopp and Wood, (1983) Mol. Immunol. 20:483-89; Sutcliffe et al., (1983) Science 219:660-66) to the amino acid sequence shown in SEQ ID NOs: 10, 11, 12, 13, or 14. Monoclonal antibodies with affinities of 10^8 M^{-1} preferably 10^9 M^{-1} to 10^{10} M^{-1} , or stronger can be made by standard procedures as described (Harlow and Lane, *supra*; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed) Academic Press, New York; and U.S. Pat. Nos. 4,381,292; 4,451,570; and 4,618,577). Antibodies may be generated against crude cell extracts of P5CR or substantially purified fragments thereof. If P5CR fragments are used, they preferably comprise at least 10, and more preferably, at least 20 contiguous amino acids of a P5CR protein. In a particular embodiment, P5CR-specific antigens and/or immunogens are coupled to carrier proteins that stimulate the immune response. For example, the subject polypeptides are covalently coupled to the keyhole limpet hemocyanin (KLH) carrier, and the conjugate is emulsified in Freund's complete adjuvant, which enhances the immune response. An appropriate immune system such as a laboratory rabbit or mouse is immunized according to conventional protocols.

The presence of P5CR-specific antibodies is assayed by an appropriate assay such as a solid phase enzyme-linked immunosorbant assay (ELISA) using immobilized corresponding P5CR polypeptides. Other assays, such as radioimmunoassays or fluorescent assays might also be used.

Chimeric antibodies specific to P5CR polypeptides can be made that contain different portions from different animal species. For instance, a human immunoglobulin constant region may be linked to a variable region of a murine mAb, such that the antibody derives its biological activity from the human antibody, and its binding specificity from the

murine fragment. Chimeric antibodies are produced by splicing together genes that encode the appropriate regions from each species (Morrison et al., Proc. Natl. Acad. Sci. (1984) 81:6851-6855; Neuberger et al., Nature (1984) 312:604-608; Takeda et al., Nature (1985) 31:452-454). Humanized antibodies, which are a form of chimeric antibodies, can be generated by grafting complementary-determining regions (CDRs) (Carlos, T. M., J. M. Harlan. 1994. Blood 84:2068-2101) of mouse antibodies into a background of human framework regions and constant regions by recombinant DNA technology (Riechmann LM, et al., 1988 Nature 323: 323-327). Humanized antibodies contain ~10% murine sequences and ~90% human sequences, and thus further reduce or eliminate immunogenicity, while retaining the antibody specificities (Co MS, and Queen C. 1991 Nature 351: 501-501; Morrison SL. 1992 Ann. Rev. Immun. 10:239-265). Humanized antibodies and methods of their production are well-known in the art (U.S. Pat. Nos. 5,530,101, 5,585,089, 5,693,762, and 6,180,370).

P5CR-specific single chain antibodies which are recombinant, single chain polypeptides formed by linking the heavy and light chain fragments of the Fv regions via an amino acid bridge, can be produced by methods known in the art (U.S. Pat. No. 4,946,778; Bird, Science (1988) 242:423-426; Huston et al., Proc. Natl. Acad. Sci. USA (1988) 85:5879-5883; and Ward et al., Nature (1989) 334:544-546).

Other suitable techniques for antibody production involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors (Huse et al., Science (1989) 246:1275-1281). As used herein, T-cell antigen receptors are included within the scope of antibody modulators (Harlow and Lane, 1988, *supra*).

The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, antibodies will be labeled by joining, either covalently or non-covalently, a substance that provides for a detectable signal, or that is toxic to cells that express the targeted protein (Menard S, et al., Int J. Biol Markers (1989) 4:131-134). A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, fluorescent emitting lanthanide metals, chemiluminescent moieties, bioluminescent moieties, magnetic particles, and the like (U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241). Also, recombinant immunoglobulins may be produced (U.S. Pat. No. 4,816,567). Antibodies to cytoplasmic polypeptides may be delivered and reach their

targets by conjugation with membrane-penetrating toxin proteins (U.S. Pat. No. 6,086,900).

When used therapeutically in a patient, the antibodies of the subject invention are typically administered parenterally, when possible at the target site, or intravenously. The therapeutically effective dose and dosage regimen is determined by clinical studies. Typically, the amount of antibody administered is in the range of about 0.1 mg/kg –to about 10 mg/kg of patient weight. For parenteral administration, the antibodies are formulated in a unit dosage injectable form (e.g., solution, suspension, emulsion) in association with a pharmaceutically acceptable vehicle. Such vehicles are inherently nontoxic and non-therapeutic. Examples are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils, ethyl oleate, or liposome carriers may also be used. The vehicle may contain minor amounts of additives, such as buffers and preservatives, which enhance isotonicity and chemical stability or otherwise enhance therapeutic potential. The antibodies' concentrations in such vehicles are typically in the range of about 1 mg/ml to about 10 mg/ml. Immunotherapeutic methods are further described in the literature (US Pat. No. 5,859,206; WO0073469).

Nucleic Acid Modulators

Other preferred P5CR-modulating agents comprise nucleic acid molecules, such as antisense oligomers or double stranded RNA (dsRNA), which generally inhibit P5CR activity. Preferred nucleic acid modulators interfere with the function of the P5CR nucleic acid such as DNA replication, transcription, translocation of the P5CR RNA to the site of protein translation, translation of protein from the P5CR RNA, splicing of the P5CR RNA to yield one or more mRNA species, or catalytic activity which may be engaged in or facilitated by the P5CR RNA.

In one embodiment, the antisense oligomer is an oligonucleotide that is sufficiently complementary to a P5CR mRNA to bind to and prevent translation, preferably by binding to the 5' untranslated region. P5CR-specific antisense oligonucleotides, preferably range from at least 6 to about 200 nucleotides. In some embodiments the oligonucleotide is preferably at least 10, 15, or 20 nucleotides in length. In other embodiments, the oligonucleotide is preferably less than 50, 40, or 30 nucleotides in length. The oligonucleotide can be DNA or RNA or a chimeric mixture or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified

at the base moiety, sugar moiety, or phosphate backbone. The oligonucleotide may include other appending groups such as peptides, agents that facilitate transport across the cell membrane, hybridization-triggered cleavage agents, and intercalating agents.

- In another embodiment, the antisense oligomer is a phosphothioate morpholino oligomer (PMO). PMOs are assembled from four different morpholino subunits, each of which contain one of four genetic bases (A, C, G, or T) linked to a six-membered morpholine ring. Polymers of these subunits are joined by non-ionic phosphodiamidate intersubunit linkages. Details of how to make and use PMOs and other antisense oligomers are well known in the art (e.g. see WO99/18193; Probst JC, Antisense Oligodeoxynucleotide and Ribozyme Design, Methods. (2000) 22(3):271-281; Summerton J, and Weller D. 1997 Antisense Nucleic Acid Drug Dev. :7:187-95; US Pat. No. 5,235,033; and US Pat No. 5,378,841).

- Alternative preferred P5CR nucleic acid modulators are double-stranded RNA species mediating RNA interference (RNAi). RNAi is the process of sequence-specific, post-transcriptional gene silencing in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene. Methods relating to the use of RNAi to silence genes in *C. elegans*, *Drosophila*, plants, and humans are known in the art (Fire A, et al., 1998 Nature 391:806-811; Fire, A. Trends Genet. 15, 358-363 (1999); Sharp, P. A. RNA interference 2001. Genes Dev. 15, 485-490 (2001); Hammond, S. M., et al., Nature Rev. Genet. 2, 110-1119 (2001); Tuschl, T. Chem. Biochem. 2, 239-245 (2001); Hamilton, A. et al., Science 286, 950-952 (1999); Hammond, S. M., et al., Nature 404, 293-296 (2000); Zamore, P. D., et al., Cell 101, 25-33 (2000); Bernstein, E., et al., Nature 409, 363-366 (2001); Elbashir, S. M., et al., Genes Dev. 15, 188-200 (2001); WO0129058; WO9932619; Elbashir SM, et al., 2001 Nature 411:494-498).
- Example VII details the use of RNAi to knock down P5CR expression in cell lines.

- Nucleic acid modulators are commonly used as research reagents, diagnostics, and therapeutics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used to elucidate the function of particular genes (see, for example, U.S. Pat. No. 6,165,790). Nucleic acid modulators are also used, for example, to distinguish between functions of various members of a biological pathway. For example, antisense oligomers have been employed as therapeutic moieties in the treatment of disease states in animals and man and have been demonstrated in numerous clinical trials to be safe and effective (Milligan JF, et al, Current Concepts in Antisense Drug Design, J Med Chem. (1993) 36:1923-1937; Tonkinson JL et al., Antisense

Oligodeoxynucleotides as Clinical Therapeutic Agents, Cancer Invest. (1996) 14:54-65). Accordingly, in one aspect of the invention, a P5CR-specific nucleic acid modulator is used in an assay to further elucidate the role of the P5CR in the p53 pathway, and/or its relationship to other members of the pathway. In another aspect of the invention, a P5CR-specific antisense oligomer is used as a therapeutic agent for treatment of p53-related disease states.

Assay Systems

The invention provides assay systems and screening methods for identifying specific modulators of P5CR activity. As used herein, an "assay system" encompasses all the components required for performing and analyzing results of an assay that detects and/or measures a particular event. In general, primary assays are used to identify or confirm a modulator's specific biochemical or molecular effect with respect to the P5CR nucleic acid or protein. In general, secondary assays further assess the activity of a P5CR modulating agent identified by a primary assay and may confirm that the modulating agent affects P5CR in a manner relevant to the p53 pathway. In some cases, P5CR modulators will be directly tested in a secondary assay.

In a preferred embodiment, the screening method comprises contacting a suitable assay system comprising a P5CR polypeptide with a candidate agent under conditions whereby, but for the presence of the agent, the system provides a reference activity (e.g. enzymatic activity), which is based on the particular molecular event the screening method detects. A statistically significant difference between the agent-biased activity and the reference activity indicates that the candidate agent modulates P5CR activity, and hence the p53 pathway.

Primary Assays

The type of modulator tested generally determines the type of primary assay.

Primary assays for small molecule modulators

For small molecule modulators, screening assays are used to identify candidate modulators. Screening assays may be cell-based or may use a cell-free system that recreates or retains the relevant biochemical reaction of the target protein (reviewed in Sittampalam GS *et al.*, Curr Opin Chem Biol (1997) 1:384-91 and accompanying references). As used herein the term "cell-based" refers to assays using live cells, dead

cells, or a particular cellular fraction, such as a membrane, endoplasmic reticulum, or mitochondrial fraction. The term "cell free" encompasses assays using substantially purified protein (either endogenous or recombinantly produced), partially purified or crude cellular extracts. Screening assays may detect a variety of molecular events, including

5 protein-DNA interactions, protein-protein interactions (*e.g.*, receptor-ligand binding), transcriptional activity (*e.g.*, using a reporter gene), enzymatic activity (*e.g.*, via a property of the substrate), activity of second messengers, immunogenicity and changes in cellular morphology or other cellular characteristics. Appropriate screening assays may use a wide range of detection methods including fluorescent, radioactive, colorimetric,

10 spectrophotometric, and amperometric methods, to provide a read-out for the particular molecular event detected.

Cell-based screening assays usually require systems for recombinant expression of P5CR and any auxiliary proteins demanded by the particular assay. Appropriate methods for generating recombinant proteins produce sufficient quantities of proteins that retain

15 their relevant biological activities and are of sufficient purity to optimize activity and assure assay reproducibility. Yeast two-hybrid and variant screens, and mass spectrometry provide preferred methods for determining protein-protein interactions and elucidation of protein complexes. In certain applications, when P5CR-interacting proteins are used in screens to identify small molecule modulators, the binding specificity of the interacting

20 protein to the P5CR protein may be assayed by various known methods such as substrate processing (*e.g.* ability of the candidate P5CR-specific binding agents to function as negative effectors in P5CR-expressing cells), binding equilibrium constants (usually at least about 10^7 M^{-1} , preferably at least about 10^8 M^{-1} , more preferably at least about 10^9 M^{-1}), and immunogenicity (*e.g.* ability to elicit P5CR specific antibody in a heterologous host

25 such as a mouse, rat, goat or rabbit). For enzymes and receptors, binding may be assayed by, respectively, substrate and ligand processing.

The screening assay may measure a candidate agent's ability to specifically bind to or modulate activity of a P5CR polypeptide, a fusion protein thereof, or to cells or membranes bearing the polypeptide or fusion protein. The P5CR polypeptide can be full

30 length or a fragment thereof that retains functional P5CR activity. The P5CR polypeptide may be fused to another polypeptide, such as a peptide tag for detection or anchoring, or to another tag. The P5CR polypeptide is preferably human P5CR, or is an ortholog or derivative thereof as described above. In a preferred embodiment, the screening assay detects candidate agent-based modulation of P5CR interaction with a binding target, such

as an endogenous or exogenous protein or other substrate that has P5CR –specific binding activity, and can be used to assess normal P5CR gene function.

Suitable assay formats that may be adapted to screen for P5CR modulators are known in the art. Preferred screening assays are high throughput or ultra high throughput and thus provide automated, cost-effective means of screening compound libraries for lead compounds (Fernandes PB, Curr Opin Chem Biol (1998) 2:597-603; Sundberg SA, Curr Opin Biotechnol 2000, 11:47-53). In one preferred embodiment, screening assays uses fluorescence technologies, including fluorescence polarization, time-resolved fluorescence, and fluorescence resonance energy transfer. These systems offer means to monitor protein-protein or DNA-protein interactions in which the intensity of the signal emitted from dye-labeled molecules depends upon their interactions with partner molecules (*e.g.*, Selvin PR, Nat Struct Biol (2000) 7:730-4; Fernandes PB, *supra*; Hertzberg RP and Pope AJ, Curr Opin Chem Biol (2000) 4:445-451).

A variety of suitable assay systems may be used to identify candidate P5CR and p53 pathway modulators (*e.g.* U.S. Pat. No. 6,020,135 (p53 modulation), U.S. Pat. Nos. 5,550,019 and 6,133,437 (apoptosis assays); and U.S. Pat. No. 6,114,132 (phosphatase and protease assays)).

Reductases are enzymes of oxidoreductase class that catalyze reactions in which metabolites are reduced. High throughput screening assays for reductases may involve scintillation (Fernandes PB. (1998) Curr Opin Chem Biol 2:597-603; Delaporte E et al. (2001) J Biomol Screen 6:225-231).

Apoptosis assays. Assays for apoptosis may be performed by terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling (TUNEL) assay. The TUNEL assay is used to measure nuclear DNA fragmentation characteristic of apoptosis (Lazebnik *et al.*, 1994, Nature 371, 346), by following the incorporation of fluorescein-dUTP (Yonehara *et al.*, 1989, J. Exp. Med. 169, 1747). Apoptosis may further be assayed by acridine orange staining of tissue culture cells (Lucas, R., et al., 1998, Blood 15:4730-41). An apoptosis assay system may comprise a cell that expresses a P5CR, and that optionally has defective p53 function (*e.g.* p53 is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the apoptosis assay system and changes in induction of apoptosis relative to controls where no test agent is added, identify candidate p53 modulating agents. In some embodiments of the invention, an apoptosis assay may be used as a secondary assay to test a candidate p53 modulating agents that is

initially identified using a cell-free assay system. An apoptosis assay may also be used to test whether P5CR function plays a direct role in apoptosis. For example, an apoptosis assay may be performed on cells that over- or under-express P5CR relative to wild type cells. Differences in apoptotic response compared to wild type cells suggests that the
5 P5CR plays a direct role in the apoptotic response. Apoptosis assays are described further in US Pat. No. 6,133,437.

Cell proliferation and cell cycle assays. Cell proliferation may be assayed via bromodeoxyuridine (BRDU) incorporation. This assay identifies a cell population
10 undergoing DNA synthesis by incorporation of BRDU into newly-synthesized DNA. Newly-synthesized DNA may then be detected using an anti-BRDU antibody (Hoshino *et al.*, 1986, Int. J. Cancer 38, 369; Campana *et al.*, 1988, J. Immunol. Meth. 107, 79), or by other means.

Cell Proliferation may also be examined using [³H]-thymidine incorporation (Chen, J.,
15 1996, Oncogene 13:1395-403; Jeoung, J., 1995, J. Biol. Chem. 270:18367-73). This assay allows for quantitative characterization of S-phase DNA syntheses. In this assay, cells synthesizing DNA will incorporate [³H]-thymidine into newly synthesized DNA. Incorporation can then be measured by standard techniques such as by counting of radioisotope in a scintillation counter (e.g., Beckman LS 3800 Liquid Scintillation
20 Counter).

Cell proliferation may also be assayed by colony formation in soft agar (Sambrook *et al.*, Molecular Cloning, Cold Spring Harbor (1989)). For example, cells transformed with P5CR are seeded in soft agar plates, and colonies are measured and counted after two weeks incubation.

25 Involvement of a gene in the cell cycle may be assayed by flow cytometry (Gray JW *et al.* (1986) Int J Radiat Biol Relat Stud Phys Chem Med 49:237-55). Cells transfected with a P5CR may be stained with propidium iodide and evaluated in a flow cytometer (available from Becton Dickinson).

Accordingly, a cell proliferation or cell cycle assay system may comprise a cell that
30 expresses a P5CR, and that optionally has defective p53 function (e.g. p53 is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the assay system and changes in cell proliferation or cell cycle relative to controls where no test agent is added, identify candidate p53 modulating agents. In some embodiments of the invention, the cell proliferation or cell cycle assay may be used as a secondary assay to

test a candidate p53 modulating agents that is initially identified using another assay system such as a cell-free kinase assay system. A cell proliferation assay may also be used to test whether P5CR function plays a direct role in cell proliferation or cell cycle. For example, a cell proliferation or cell cycle assay may be performed on cells that over- or under-express P5CR relative to wild type cells. Differences in proliferation or cell cycle compared to wild type cells suggests that the P5CR plays a direct role in cell proliferation or cell cycle.

Angiogenesis. Angiogenesis may be assayed using various human endothelial cell systems, such as umbilical vein, coronary artery, or dermal cells. Suitable assays include Alamar Blue based assays (available from Biosource International) to measure proliferation; migration assays using fluorescent molecules, such as the use of Becton Dickinson Falcon HTS FluoroBlock cell culture inserts to measure migration of cells through membranes in presence or absence of angiogenesis enhancer or suppressors; and tubule formation assays based on the formation of tubular structures by endothelial cells on Matrigel® (Becton Dickinson). Accordingly, an angiogenesis assay system may comprise a cell that expresses a P5CR, and that optionally has defective p53 function (e.g. p53 is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the angiogenesis assay system and changes in angiogenesis relative to controls where no test agent is added, identify candidate p53 modulating agents. In some embodiments of the invention, the angiogenesis assay may be used as a secondary assay to test a candidate p53 modulating agents that is initially identified using another assay system. An angiogenesis assay may also be used to test whether P5CR function plays a direct role in cell proliferation. For example, an angiogenesis assay may be performed on cells that over- or under-express P5CR relative to wild type cells. Differences in angiogenesis compared to wild type cells suggests that the P5CR plays a direct role in angiogenesis.

Hypoxic induction. The alpha subunit of the transcription factor, hypoxia inducible factor-1 (HIF-1), is upregulated in tumor cells following exposure to hypoxia in vitro. Under hypoxic conditions, HIF-1 stimulates the expression of genes known to be important in tumour cell survival, such as those encoding glycolytic enzymes and VEGF. Induction of such genes by hypoxic conditions may be assayed by growing cells transfected with P5CR in hypoxic conditions (such as with 0.1% O₂, 5% CO₂, and

balance N₂, generated in a Napco 7001 incubator (Precision Scientific)) and normoxic conditions, followed by assessment of gene activity or expression by Taqman®. For example, a hypoxic induction assay system may comprise a cell that expresses a P5CR, and that optionally has a mutated p53 (e.g. p53 is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the hypoxic induction assay system and changes in hypoxic response relative to controls where no test agent is added, identify candidate p53 modulating agents. In some embodiments of the invention, the hypoxic induction assay may be used as a secondary assay to test a candidate p53 modulating agents that is initially identified using another assay system. A hypoxic induction assay may also be used to test whether P5CR function plays a direct role in the hypoxic response. For example, a hypoxic induction assay may be performed on cells that over- or under-express P5CR relative to wild type cells. Differences in hypoxic response compared to wild type cells suggests that the P5CR plays a direct role in hypoxic induction.

15

Cell adhesion. Cell adhesion assays measure adhesion of cells to purified adhesion proteins, or adhesion of cells to each other, in presence or absence of candidate modulating agents. Cell-protein adhesion assays measure the ability of agents to modulate the adhesion of cells to purified proteins. For example, recombinant proteins are produced, diluted to 2.5g/mL in PBS, and used to coat the wells of a microtiter plate. The wells used for negative control are not coated. Coated wells are then washed, blocked with 1% BSA, and washed again. Compounds are diluted to 2× final test concentration and added to the blocked, coated wells. Cells are then added to the wells, and the unbound cells are washed off. Retained cells are labeled directly on the plate by adding a membrane-permeable fluorescent dye, such as calcein-AM, and the signal is quantified in a fluorescent microplate reader.

Cell-cell adhesion assays measure the ability of agents to modulate binding of cell adhesion proteins with their native ligands. These assays use cells that naturally or recombinantly express the adhesion protein of choice. In an exemplary assay, cells expressing the cell adhesion protein are plated in wells of a multiwell plate. Cells expressing the ligand are labeled with a membrane-permeable fluorescent dye, such as BCECF, and allowed to adhere to the monolayers in the presence of candidate agents. Unbound cells are washed off, and bound cells are detected using a fluorescence plate reader.

High-throughput cell adhesion assays have also been described. In one such assay, small molecule ligands and peptides are bound to the surface of microscope slides using a microarray spotter, intact cells are then contacted with the slides, and unbound cells are washed off. In this assay, not only the binding specificity of the peptides and modulators
5 against cell lines are determined, but also the functional cell signaling of attached cells using immunofluorescence techniques in situ on the microchip is measured (Falsey JR et al., Bioconjug Chem. 2001 May-Jun;12(3):346-53).

Primary assays for antibody modulators

10 For antibody modulators, appropriate primary assays test is a binding assay that tests the antibody's affinity to and specificity for the P5CR protein. Methods for testing antibody affinity and specificity are well known in the art (Harlow and Lane, 1988, 1999, *supra*). The enzyme-linked immunosorbant assay (ELISA) is a preferred method for detecting P5CR-specific antibodies; others include FACS assays, radioimmunoassays, and
15 fluorescent assays.

Primary assays for nucleic acid modulators

For nucleic acid modulators, primary assays may test the ability of the nucleic acid modulator to inhibit or enhance P5CR gene expression, preferably mRNA expression. In
20 general, expression analysis comprises comparing P5CR expression in like populations of cells (*e.g.*, two pools of cells that endogenously or recombinantly express P5CR) in the presence and absence of the nucleic acid modulator. Methods for analyzing mRNA and protein expression are well known in the art. For instance, Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR (*e.g.*, using the TaqMan®, PE Applied
25 Biosystems), or microarray analysis may be used to confirm that P5CR mRNA expression is reduced in cells treated with the nucleic acid modulator (*e.g.*, Current Protocols in Molecular Biology (1994) Ausubel FM *et al.*, eds., John Wiley & Sons, Inc., chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm DH and Guiseppi-Elie, A Curr Opin Biotechnol 2001, 12:41-47).
30 Protein expression may also be monitored. Proteins are most commonly detected with specific antibodies or antisera directed against either the P5CR protein or specific peptides. A variety of means including Western blotting, ELISA, or in situ detection, are available (Harlow E and Lane D, 1988 and 1999, *supra*).

Secondary Assays

Secondary assays may be used to further assess the activity of P5CR-modulating agent identified by any of the above methods to confirm that the modulating agent affects P5CR in a manner relevant to the p53 pathway. As used herein, P5CR-modulating agents encompass candidate clinical compounds or other agents derived from previously identified modulating agent. Secondary assays can also be used to test the activity of a modulating agent on a particular genetic or biochemical pathway or to test the specificity of the modulating agent's interaction with P5CR.

Secondary assays generally compare like populations of cells or animals (*e.g.*, two pools of cells or animals that endogenously or recombinantly express P5CR) in the presence and absence of the candidate modulator. In general, such assays test whether treatment of cells or animals with a candidate P5CR-modulating agent results in changes in the p53 pathway in comparison to untreated (or mock- or placebo-treated) cells or animals. Certain assays use "sensitized genetic backgrounds", which, as used herein, describe cells or animals engineered for altered expression of genes in the p53 or interacting pathways.

Cell-based assays

Cell based assays may use a variety of mammalian cell lines known to have defective p53 function (*e.g.* SAOS-2 osteoblasts, H1299 lung cancer cells, C33A and HT3 cervical cancer cells, HT-29 and DLD-1 colon cancer cells, among others, available from American Type Culture Collection (ATCC), Manassas, VA). Cell based assays may detect endogenous p53 pathway activity or may rely on recombinant expression of p53 pathway components. Any of the aforementioned assays may be used in this cell-based format. Candidate modulators are typically added to the cell media but may also be injected into cells or delivered by any other efficacious means.

Animal Assays

A variety of non-human animal models of normal or defective p53 pathway may be used to test candidate P5CR modulators. Models for defective p53 pathway typically use genetically modified animals that have been engineered to mis-express (*e.g.*, over-express or lack expression in) genes involved in the p53 pathway. Assays generally require systemic delivery of the candidate modulators, such as by oral administration, injection, etc.

In a preferred embodiment, p53 pathway activity is assessed by monitoring neovascularization and angiogenesis. Animal models with defective and normal p53 are used to test the candidate modulator's affect on P5CR in Matrigel® assays. Matrigel® is an extract of basement membrane proteins, and is composed primarily of laminin, collagen IV, and heparin sulfate proteoglycan. It is provided as a sterile liquid at 4° C, but rapidly forms a solid gel at 37° C. Liquid Matrigel® is mixed with various angiogenic agents, such as bFGF and VEGF, or with human tumor cells which over-express the P5CR. The mixture is then injected subcutaneously(SC) into female athymic nude mice (Taconic, Germantown, NY) to support an intense vascular response. Mice with Matrigel® pellets may be dosed via oral (PO), intraperitoneal (IP), or intravenous (IV) routes with the candidate modulator. Mice are euthanized 5 - 12 days post-injection, and the Matrigel® pellet is harvested for hemoglobin analysis (Sigma plasma hemoglobin kit). Hemoglobin content of the gel is found to correlate the degree of neovascularization in the gel.

In another preferred embodiment, the effect of the candidate modulator on P5CR is assessed via tumorigenicity assays. In one example, xenograft human tumors are implanted SC into female athymic mice, 6-7 week old, as single cell suspensions either from a pre-existing tumor or from *in vitro* culture. The tumors which express the P5CR endogenously are injected in the flank, 1×10^5 to 1×10^7 cells per mouse in a volume of 100 μ L using a 27gauge needle. Mice are then ear tagged and tumors are measured twice weekly. Candidate modulator treatment is initiated on the day the mean tumor weight reaches 100 mg. Candidate modulator is delivered IV, SC, IP, or PO by bolus administration. Depending upon the pharmacokinetics of each unique candidate modulator, dosing can be performed multiple times per day. The tumor weight is assessed by measuring perpendicular diameters with a caliper and calculated by multiplying the measurements of diameters in two dimensions. At the end of the experiment, the excised tumors may be utilized for biomarker identification or further analyses. For immunohistochemistry staining, xenograft tumors are fixed in 4% paraformaldehyde, 0.1M phosphate, pH 7.2, for 6 hours at 4°C, immersed in 30% sucrose in PBS, and rapidly frozen in isopentane cooled with liquid nitrogen.

30

Diagnostic and therapeutic uses

Specific P5CR-modulating agents are useful in a variety of diagnostic and therapeutic applications where disease or disease prognosis is related to defects in the p53 pathway, such as angiogenic, apoptotic, or cell proliferation disorders. Accordingly, the invention

also provides methods for modulating the p53 pathway in a cell, preferably a cell pre-determined to have defective p53 function, comprising the step of administering an agent to the cell that specifically modulates P5CR activity. Preferably, the modulating agent produces a detectable phenotypic change in the cell indicating that the p53 function is restored, i.e., for example, the cell undergoes normal proliferation or progression through the cell cycle.

The discovery that P5CR is implicated in p53 pathway provides for a variety of methods that can be employed for the diagnostic and prognostic evaluation of diseases and disorders involving defects in the p53 pathway and for the identification of subjects having a predisposition to such diseases and disorders.

Various expression analysis methods can be used to diagnose whether P5CR expression occurs in a particular sample, including Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR, and microarray analysis. (*e.g.*, Current Protocols in Molecular Biology (1994) Ausubel FM *et al.*, eds., John Wiley & Sons, Inc., chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm and Guiseppi-Elie, Curr Opin Biotechnol 2001, 12:41-47). Tissues having a disease or disorder implicating defective p53 signaling that express a P5CR, are identified as amenable to treatment with a P5CR modulating agent. In a preferred application, the p53 defective tissue overexpresses a P5CR relative to normal tissue. For example, a Northern blot analysis of mRNA from tumor and normal cell lines, or from tumor and matching normal tissue samples from the same patient, using full or partial P5CR cDNA sequences as probes, can determine whether particular tumors express or overexpress P5CR. Alternatively, the TaqMan® is used for quantitative RT-PCR analysis of P5CR expression in cell lines, normal tissues and tumor samples (PE Applied Biosystems).

Various other diagnostic methods may be performed, for example, utilizing reagents such as the P5CR oligonucleotides, and antibodies directed against a P5CR, as described above for: (1) the detection of the presence of P5CR gene mutations, or the detection of either over- or under-expression of P5CR mRNA relative to the non-disorder state; (2) the detection of either an over- or an under-abundance of P5CR gene product relative to the non-disorder state; and (3) the detection of perturbations or abnormalities in the signal transduction pathway mediated by P5CR.

Thus, in a specific embodiment, the invention is drawn to a method for diagnosing a disease in a patient, the method comprising: a) obtaining a biological sample from the

patient; b) contacting the sample with a probe for P5CR expression; c) comparing results from step (b) with a control; and d) determining whether step (c) indicates a likelihood of disease. Preferably, the disease is cancer, most preferably a cancer as shown in TABLE 1. The probe may be either DNA or protein, including an antibody.

5

EXAMPLES

The following experimental section and examples are offered by way of illustration and not by way of limitation.

10 I. Drosophila p53 screen

The *Drosophila* p53 gene was overexpressed specifically in the wing using the vestigial margin quadrant enhancer. Increasing quantities of *Drosophila* p53 (titrated using different strength transgenic inserts in 1 or 2 copies) caused deterioration of normal wing morphology from mild to strong, with phenotypes including disruption of pattern and
15 polarity of wing hairs, shortening and thickening of wing veins, progressive crumpling of the wing and appearance of dark "death" inclusions in wing blade. In a screen designed to identify enhancers and suppressors of *Drosophila* p53, homozygous females carrying two copies of p53 were crossed to 5663 males carrying random insertions of a piggyBac transposon (Fraser M *et al.*, Virology (1985) 145:356-361). Progeny containing insertions
20 were compared to non-insertion-bearing sibling progeny for enhancement or suppression of the p53 phenotypes. Sequence information surrounding the piggyBac insertion site was used to identify the modifier genes. Modifiers of the wing phenotype were identified as members of the p53 pathway. *Drosophila* p5cr was an enhancer of the wing phenotype. Human orthologs of the modifiers are referred to herein as P5CR.

25

II. P5CR assay

In an assay based on fluorescence intensity, P5CR is quantified using a homogeneous fluorescence HTS assay format, not requiring any wash steps. The assay is carried out in plates with any number of wells, such as 96, 384, 1536, or others.

30 In this assay, P5CR catalyzes the reduction of Pyrroline 5 carboxylate to proline using NADPH. The reaction is allowed to proceed for a period of time, and then stopped. Remaining NADPH is quantitated via a coupling reaction with resazurine and diaphorase to produce highly fluorescent compound resorufin. As such, an inhibited P5CR reaction is

characterized by a large resorufin signal. Conversely, an uninhibited reaction produces a small resorufin signal.

Reaction conditions include 20 μ M NADPH, and 100 μ M P5C in 30mM potassium phosphate buffer (pH 7.0), in a total volume of up to 80 μ l. Reactants are incubated for 1
5 hr to allow the reaction to proceed. Resazurine and diaphorase are then added at 20 μ M and 50mU, respectively. Increase in fluorescence intensity is then monitored on a plate reader, with excitation and emission intensities set to 540 and 605 nm, respectively. Alternatively, reaction progress is monitored directly by observing the consumption of NADPH either fluorimetrically (excitation/emission = 340/360 nm) or
10 spectrophotometrically at 340 nm.

III. High-Throughput In Vitro Fluorescence Polarization Assay

Fluorescently-labeled P5CR peptide/substrate are added to each well of a 96-well microtiter plate, along with a test agent in a test buffer (10 mM HEPES, 10 mM NaCl, 6
15 mM magnesium chloride, pH 7.6). Changes in fluorescence polarization, determined by using a Fluorolite FPM-2 Fluorescence Polarization Microtiter System (Dynatech Laboratories, Inc), relative to control values indicates the test compound is a candidate modifier of P5CR activity.

20 IV. High-Throughput In Vitro Binding Assay.

³³P-labeled P5CR peptide is added in an assay buffer (100 mM KCl, 20 mM HEPES pH 7.6, 1 mM MgCl₂, 1% glycerol, 0.5% NP-40, 50 mM beta-mercaptoethanol, 1 mg/ml BSA, cocktail of protease inhibitors) along with a test agent to the wells of a Neutralite-
avidin coated assay plate and incubated at 25°C for 1 hour. Biotinylated substrate is then
15 added to each well and incubated for 1 hour. Reactions are stopped by washing with PBS, and counted in a scintillation counter. Test agents that cause a difference in activity relative to control without test agent are identified as candidate p53 modulating agents.

V. Immunoprecipitations and Immunoblotting

10 For coprecipitation of transfected proteins, 3 \times 10⁶ appropriate recombinant cells containing the P5CR proteins are plated on 10-cm dishes and transfected on the following day with expression constructs. The total amount of DNA is kept constant in each transfection by adding empty vector. After 24 h, cells are collected, washed once with phosphate-buffered saline and lysed for 20 min on ice in 1 ml of lysis buffer containing 50

mM Hepes, pH 7.9, 250 mM NaCl, 20 mM -glycerophosphate, 1 mM sodium orthovanadate, 5 mM p-nitrophenyl phosphate, 2 mM dithiothreitol, protease inhibitors (complete, Roche Molecular Biochemicals), and 1% Nonidet P-40. Cellular debris is removed by centrifugation twice at 15,000 × g for 15 min. The cell lysate is incubated
5 with 25 µl of M2 beads (Sigma) for 2 h at 4 °C with gentle rocking.

After extensive washing with lysis buffer, proteins bound to the beads are solubilized by boiling in SDS sample buffer, fractionated by SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membrane and blotted with the indicated antibodies. The reactive bands are visualized with horseradish peroxidase coupled to the
10 appropriate secondary antibodies and the enhanced chemiluminescence (ECL) Western blotting detection system (Amersham Pharmacia Biotech).

VI. Expression analysis

All cell lines used in the following experiments are NCI (National Cancer Institute)
15 lines, and are available from ATCC (American Type Culture Collection, Manassas, VA 20110-2209). Normal and tumor tissues were obtained from Impath, UC Davis, Clontech, Stratagene, and Ambion.

TaqMan analysis was used to assess expression levels of the disclosed genes in various samples.

20 RNA was extracted from each tissue sample using Qiagen (Valencia, CA) RNeasy kits, following manufacturer's protocols, to a final concentration of 50ng/µl. Single stranded cDNA was then synthesized by reverse transcribing the RNA samples using random hexamers and 500ng of total RNA per reaction, following protocol 4304965 of Applied Biosystems (Foster City, CA, <http://www.appliedbiosystems.com/>).

25 Primers for expression analysis using TaqMan assay (Applied Biosystems, Foster City, CA) were prepared according to the TaqMan protocols, and the following criteria: a) primer pairs were designed to span introns to eliminate genomic contamination, and b) each primer pair produced only one product.

Taqman reactions were carried out following manufacturer's protocols, in 25 µl total
30 volume for 96-well plates and 10 µl total volume for 384-well plates, using 300nM primer and 250 nM probe, and approximately 25ng of cDNA. The standard curve for result analysis was prepared using a universal pool of human cDNA samples, which is a mixture of cDNAs from a wide variety of tissues so that the chance that a target will be present in

appreciable amounts is good. The raw data were normalized using 18S rRNA (universally expressed in all tissues and cells).

For each expression analysis, tumor tissue samples were compared with matched normal tissues from the same patient. A gene was considered overexpressed in a tumor when the level of expression of the gene was 2 fold or higher in the tumor compared with its matched normal sample. In cases where normal tissue was not available, a universal pool of cDNA samples was used instead. In these cases, a gene was considered overexpressed in a tumor sample when the difference of expression levels between a tumor sample and the average of all normal samples from the same tissue type was greater than 2 times the standard deviation of all normal samples (i.e., $\text{Tumor} - \text{average}(\text{all normal samples}) > 2 \times \text{STDEV}(\text{all normal samples})$).

Results are shown in Table 1. Data presented in bold indicate that greater than 50% of tested tumor samples of the tissue type indicated in row 1 exhibited over expression of the gene listed in column 1, relative to normal samples. Underlined data indicates that between 25% to 49% of tested tumor samples exhibited over expression. A modulator identified by an assay described herein can be further validated for therapeutic effect by administration to a tumor in which the gene is overexpressed. A decrease in tumor growth confirms therapeutic utility of the modulator. Prior to treating a patient with the modulator, the likelihood that the patient will respond to treatment can be diagnosed by obtaining a tumor sample from the patient, and assaying for expression of the gene targeted by the modulator. The expression data for the gene(s) can also be used as a diagnostic marker for disease progression. The assay can be performed by expression analysis as described above, by antibody directed to the gene target, or by any other available detection method.

Table 1

NA GI#		breast		colon		kidney		lung		ovary	
189497 (SEQ ID NO:1)	P5CR1	0	3	<u>12</u>	<u>30</u>	0	0	7	13	4	7

VII. P5CR RNAi

RNAi experiments were carried out to knock down expression of P5CR using small interfering RNAs (siRNA, Elbashir et al, *supra*). The sequence of SEQ ID NO:1 was used as a template for siRNAs. siRNAs (21mer, double stranded RNA oligos with 2 base 3' overhangs) were transfected into SW620 cells, a colon carcinoma cell line (available from

American Type Culture Collection (ATCC), Manassas, VA) at 200 nM using oligofectamine (Invitrogen) (day 1). Cells were incubated for 2 days at 37 degrees, then split a second time (day 3) and re-transfected the next day (day 4). The experiment was ended on day 7, when cells were harvested for protein extracts and used in western analysis.

P5CR protein was specifically knocked down as measured by western analysis using a mouse polyclonal antibody raised against P5CR. This was in comparison with negative controls for mock transfection, and a non-specific siRNA (luciferase).

10 VIII. P5CR Immunohistochemistry

Immunohistochemistry was used to localize P5CR protein in human tissue sections according to known methods (Thomas Boenisch, ed. (2001) Handbook, Immunochemical Staining Methods, 3rd Edition, Dako Corporation, Carpinteria, CA, USA, <http://www.dakousa.com/ihcbook/hbcontent.htm>). P5CR was localized with a purified rabbit polyclonal antibody, and gave a punctate cytoplasmic staining pattern. Weak staining for P5CR was seen in normal breast and salivary gland. Screening of cancer tissues showed P5CR protein was present in breast, stomach, prostate, bladder, and salivary gland tumors.

WHAT IS CLAIMED IS:

1. A method of identifying a candidate p53 pathway modulating agent, said method
5 comprising the steps of:
 - (a) providing an assay system comprising a purified P5CR polypeptide or nucleic acid or a functionally active fragment or derivative thereof;
 - (b) contacting the assay system with a test agent under conditions whereby, but for the presence of the test agent, the system provides a reference activity; and
 - 10 (c) detecting a test agent-biased activity of the assay system, wherein a difference between the test agent-biased activity and the reference activity identifies the test agent as a candidate p53 pathway modulating agent.
2. The method of Claim 1 wherein the assay system comprises cultured cells that
15 express the P5CR polypeptide.
3. The method of Claim 2 wherein the cultured cells additionally have defective p53 function.
- 20 4. The method of Claim 1 wherein the assay system includes a screening assay comprising a P5CR polypeptide, and the candidate test agent is a small molecule modulator.
5. The method of Claim 4 wherein the assay is a reductase assay.
25
6. The method of Claim 1 wherein the assay system is selected from the group consisting of an apoptosis assay system, a cell proliferation assay system, an angiogenesis assay system, and a hypoxic induction assay system.
- 30 7. The method of Claim 1 wherein the assay system includes a binding assay comprising a P5CR polypeptide and the candidate test agent is an antibody.
8. The method of Claim 1 wherein the assay system includes an expression assay comprising a P5CR nucleic acid and the candidate test agent is a nucleic acid modulator.

9. The method of claim 8 wherein the nucleic acid modulator is an antisense oligomer.
- 5 10. The method of Claim 8 wherein the nucleic acid modulator is a PMO.
11. The method of Claim 1 additionally comprising:
(d) administering the candidate p53 pathway modulating agent identified in (c) to a model system comprising cells defective in p53 function and, detecting a phenotypic
10 change in the model system that indicates that the p53 function is restored.
12. The method of Claim 11 wherein the model system is a mouse model with defective p53 function.
- 15 13. A method for modulating a p53 pathway of a cell comprising contacting a cell defective in p53 function with a candidate modulator that specifically binds to a P5CR polypeptide comprising an amino acid sequence selected from group consisting of SEQ ID NOs: 10, 11, 12, 13, and 14 whereby p53 function is restored.
- 20 14. The method of claim 13 wherein the candidate modulator is administered to a vertebrate animal predetermined to have a disease or disorder resulting from a defect in p53 function.
15. The method of Claim 13 wherein the candidate modulator is selected from the
25 group consisting of an antibody and a small molecule.
16. The method of Claim 1, comprising the additional steps of:
(d) providing a secondary assay system comprising cultured cells or a non-human animal expressing P5CR ,
30 (e) contacting the secondary assay system with the test agent of (b) or an agent derived therefrom under conditions whereby, but for the presence of the test agent or agent derived therefrom, the system provides a reference activity; and
(f) detecting an agent-biased activity of the second assay system,

wherein a difference between the agent-biased activity and the reference activity of the second assay system confirms the test agent or agent derived therefrom as a candidate p53 pathway modulating agent,
and wherein the second assay detects an agent-biased change in the p53 pathway.

5

17. The method of Claim 16 wherein the secondary assay system comprises cultured cells.

18. The method of Claim 16 wherein the secondary assay system comprises a non-
10 human animal.

19. The method of Claim 18 wherein the non-human animal mis-expresses a p53 pathway gene.

15 20. A method of modulating p53 pathway in a mammalian cell comprising contacting the cell with an agent that specifically binds a P5CR polypeptide or nucleic acid.

21. The method of Claim 20 wherein the agent is administered to a mammalian animal predetermined to have a pathology associated with the p53 pathway.

20

22. The method of Claim 20 wherein the agent is a small molecule modulator, a nucleic acid modulator, or an antibody.

23. A method for diagnosing a disease in a patient comprising:

25

- (a) obtaining a biological sample from the patient;
- (b) contacting the sample with a probe for P5CR expression;
- (c) comparing results from step (b) with a control;
- (d) determining whether step (c) indicates a likelihood of disease.

30 24. The method of claim 23 wherein said disease is cancer.

25. The method according to claim 24, wherein said cancer is a cancer as shown in Table 1 as having >25% expression level.

35

SEQUENCE LISTING

<110> EXELIXIS, INC.

<120> P5CRs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE

<130> EX02-055C-PC

<150> US 60/296,080

<151> 2001-06-05

<150> US 60/328,509

<151> 2001-10-10

<160> 14

<170> PatentIn version 3.1

<210> 1

<211> 1792

<212> DNA

<213> Homo sapiens

<400> 1

```

ctccggacag catgagcgtg ggcttcacg gcgctggcca gctggctttt gccctggcca      60
agggcttcac agcagcaggc gtcttggtg cccacaagat aatggctagc tccccagaca      120
tggacctggc cacagtttct gctctcagga agatgggggt gaagttgaca cccacaaca      180
aggagacggg gcagcacagt gatgtgctct tcctggctgt gaagccacac atcatccct      240
tcacctctga tgaaataggc gccgacattg aggacagaca cattgtggtg tcctgcggg      300
ccggcgctac catcagctcc attgagaaga agctgtcagc gtttcggcca gccccaggg      360
tcacccgctg catgaccaac actccagtcg tggtgcggga gggggccacc gtgtatgcca      420
caggcacgca cggccagggt gaggacggga ggctcatgga gcagctgctg agcacgggtg      480
gcttctgcac ggaggtggaa gaggacctga ttgatgccgt cacggggctc agtggcagcg      540
gccccgccta cgcattcaca gccctggatg ccctggctga tgggggtgtg aagatgggac      600
ttccaaggcg cctggcagtc cgctcgggg cccaggccct cctgggggct gccaaagatgc      660
tgctgcactc agaacagcac ccaggccagc tcaaggacaa cgtcagctct cctggtgggg      720
ccaccatcca tgccttgcac gtgctggaga gtgggggctt ccgctccctg ctcatcaacg      780
ctgtggaggc ctctgcac cgcacacggg agctgcagtc catggctgac caggagcagg      840
tgtcaccagc cgccatcaag aagaccatcc tggacaaggt gaagctggac tcccctgcag      900
ggaccgctct gtcgccttct ggccacacca agctgctccc ccgcagcctg gccccagcg      960
gcaaggattg acacgtcctg cctgaccacc atoctgccac caccttctct tctcttgtca     1020
ctaggggggac taggggggtcc ccaaagtggc ccactttctg tggctctgat cagcgcaggg     1080
gccagccagg gacatagcca gggagggggc acatcacttc ccactggaaa tctctgtggt     1140

```

```

ctgcaagtgc ttcccagccc agaacagggg tggattcccc aacctcaacc tcctttcttc 1200
tctgtctcca aaccatgtca ggaccacctt cctctagagc tcgggagccc ggagggctct 1260
caccactcc tactccagta tcagctggca cgggctcctt cctgagagca aaggtcaagg 1320
acccctctg tgaaggtca gcagaggtgg gatccacgc cccctcccg cccctccctg 1380
ccctccatc agggagaaac ctctccttc cgtgtgagaa gggccagagg gtccaggcat 1440
cccaagtcca gcgtgaaggg ccacagcccc tcttggtgc caagcacgca gatcccatgg 1500
acatttgagg aaagggctcc ttgggctgct ggtgaacttc tgtggccacc acctcctgct 1560
cctgacctcc ctgggagggg gctatcagtt ctgtcctggc cctttcagtt ttataagttg 1620
gtttccagcc cccagtgtcc tgacttctgt ctgccacatg aggagggagg ccctgcctgt 1680
gtgggagggg ggttactgtg ggtggaatag tggaggcctt caactgatta gacaaggccc 1740
gccacatct tggagggcat ctgccttact gattaaaatg tcaatgtaat ct 1792

```

```

<210> 2
<211> 2331
<212> DNA
<213> Homo sapiens

```

```

<400> 2
agcgcagcgg cgtccgaggc aacaagatgg cagctgcgga gccgtctccg cggcgcgtgg 60
gcttcgtggg cgcgggcccgc atggcggggg ccatcgcgca gggcctcatc agagcaggaa 120
aagtggaagc tcagcacata ctggccagtg caccaacaga caggaaccta tgtcactttc 180
aagctctggg ttgccggacc acgcaactca accaggaggt gctacagagc tgctgctcg 240
tcattcttgc caccaagcct catgtgctgc cagctgtcct ggcagagggt gctcctgtgg 300
tcaccactga acacatcttg gtgtccgtgg ctgctggggg gtctctgagc acctggagg 360
agctgctgcc cccaaacaca cgggtgctgc gggctctgcc caacctgccc tgtgtgggtc 420
aggaaggggc catagtgatg gcgcggggcc gccacgtggg gagcagcgag accaagctcc 480
tgcagcatct gctggaggcc tgtgggcggg gtgaggaggt gcctgaagcc tacgtcgaca 540
tccacactgg cctcagtggc agtggcgtgg ccttcgtgtg tgcatctctc gaggccttg 600
ctgaaggagc cgtcaagatg ggcattgccc gcagcctggc ccaccgcatc gctgcccaga 660
ccctgctggg gacggccaag atgctgctgc acgagggcca acaccagcc cagctgcgct 720
cagacgtgtg cccccgggt ggcaccacca tctatggact ccacgcctg gagcagggcg 780
ggctgcgagc agccaccatg agcgcctggg aggtgccac ctgccgggccc aaggagctca 840
gcagaaagta ggctgggctc tggccatcct ttctgcctc tgtgccctg cctctccctg 900
tgtcccttcc cctgaggact gcggctccct ccctcctgca tgagggctct ctactgctcc 960
ttctccctt gcacaggga atgcaggggg caggacttgg gaggttccag caggcggggg 1020

```

```

agcccccacc agtggggaca ctctccctc ccagtgagc agaaggcacc gtggtggtgg 1080
ctctgcccct tgctgcagtg agcccacctt gctgcaacat tggttctgag gggcccaaga 1140
gatggcgtct tggtcatttg cccgcatggt tgggcagttg gttgaggcca tgaacagaac 1200
ttacggtaac aggcacggct ggcccaatgc ctggtctgga gctggagctt gcctttggct 1260
ttccaggtgg ctccgtgcag ctacagccag gccggctgcc tcatctcagc tctagggggc 1320
acgagccata tggggtctgc acaagagacc ctctcccctg cagtaaagcc aggggccctg 1380
gcctgatggg gcccccatgg ggagctggag cctgccctgc agcctggaga agagggtggc 1440
tgtggtgggc gtgctcatcc cctgctaagg agcaggagct gctgggccag gtctgaggca 1500
gtgctggggg ggcaccaggt gggcagtggt aggtgggggtg gcttgaggtc tgggagggtg 1560
gccctggcca gccaggacac atgcagaccc ctggcttagt ctggatacag gctccctctt 1620
tcctcccaat cctaagctcc tgacaagtgg ccagggtggc ctgggccctc ctgcccctg 1680
cctaggtcag gggctcctgga ataccccgta gctctggcac caccacactg gcctctgatg 1740
gcaagacttg gccctccac ctgtccctaa cggacggcag gtcaggaaag ccaggactca 1800
ggggagaagc aaaccccag gattgaaggc tagggttcta gggcctttgg gtggggaggg 1860
cccgggccgg acagcctcag ctccgtcccc tgccccacaa gattcacctg ggcctccagt 1920
cccacgctgg ccccaactgc tgcagctctc ggcttcgcc caacagcctc tggagggtgag 1980
gcgggagcat gccctcagcg aggtggggcg gcgggtcctg ctgtgccatc tcctgtgcg 2040
cctgagcaga tcaatccacc agtgcaaac agggctaacg gcacctgcag gacagcagca 2100
cgctccatcc ctcatgtca gctgcctctg cggccacgga cttctgcct tcatctgctc 2160
tctcttactc tcctgagcct agcccgctcg taagctccct cccctgcctg gttcccaggg 2220
caggctgact cagttgactg cttggtccaa gcctggccct ggcacttgtc agggtcagcc 2280
taaggagatg ggaataaaga ggccagagag caccaagtga gctcatgttt c 2331

```

```

<210> 3
<211> 1848
<212> DNA
<213> Homo sapiens

```

```

<400> 3
ggcacgaggg ccatctgtgg gggcttttgg ccaggggtct ccggacagca tgagcgtggg 60
cttcatcggc gctggccagc tggcttttgc cctggccaag ggcttcacag cagcaggcgt 120
cttggtgcc cacaagataa tggctagctc ccagacatg gacctggcca cagtttctgc 180
tctcaggaag atgggggtga agttgacacc ccacaacaag gagacggtgc agcacagtga 240
tgtgctcttc ctggctgtga agccacacat catccccttc atcctggatg aaataggcgc 300

```



```

cgacattgag gacagacaca ttgtggtgtc ctgcgcggcc ggcgtcacca tcagctccat   360
tgagaagaag ctgtcagcgt ttcggccagc cccaggggtc atccgctgca tgaccaaacac   420
tccagtcgtg gtgcgggagg gggccaccgt gtatgccaca ggcacgcacg cccaggtgga   480
ggacgggagg ctcattggagc agctgctgag cagcgtgggc ttctgcacgg aggtggaaga   540
ggacctgatt gatgccgtca cggggctcag tggcagcggc cccgcctacg cattcacagc   600
cctggatgcc ctggctgatg ggggcgtgaa gatgggactt ccaaggcgcc tggcagtcctg   660
cctcggggcc caggccctcc tgggggctgc caagatgctg ctgcactcag aacagcaccc   720
aggccagctc aaggacaacg tcagctctcc tggtagggcc accatccatg ccttgcatgt   780
gctggagagt gggggcttcc gctccctgct catcaacgct gtggaggcct cctgcatccg   840
cacacgggag ctgcagtcca tggctgacca ggagcagggtg tcaccagccg ccatcaagaa   900
gaccatcctg gacaagggtga agctggactc ccctgcaggg accgctctgt cgccttctgg   960
ccacaccaag ctgctcccc gcagcctggc cccagcgggc aaggattgac acgtcctgcc  1020
tgaccaccat cctgccacca ccttctcttc tcttgctact aggggggacta ggggggtccc  1080
aaagtggccc actttctgtg gctctgatca gcgcaggggc cagccaggga catagccagg  1140
gagggggccac atcacttccc actggaaatc tctgtggtct gcaagtgctt cccagcccag  1200
aacaggggtg gattcccaaa cctcaacctc ctttcttctc tgctcccaaa ccatgtcagg  1260
accaccttcc tctagagctc gggagcccg agggctctca cccactccta ctccagtatc  1320
agctggcacg ggctccttcc tgagagcaaa ggtcaaggac cccctctgtg aaggctcagc  1380
agaggtggga tcccacgccc cctcccgccc cctccctgcc ctccattcag ggagaaacct  1440
ctccttcccg tgtgagaagg gccagagggt ccaggcatcc caagtccagc gtgaagggcc  1500
acagcccctc ttggctgcca agcacgcaga tcccatggac atttggggaa agggctcctt  1560
gggctgctgg tgaacttctg tggccaccac ctctgctcc tgacctccct gggaggggtgc  1620
tatcagttct gtcttgccc ttccagtttt ataagttggt ttccagcccc cagtgtcctg  1680
acttctgtct gccacatgag gagggaggcc ctgcctgtgt gggaggggtg ttactgtggg  1740
tggaatagtg gaggccttca actgattaga caaggccgc ccacatcttg gagggcatct  1800
gccttactga ttaaaatgtc aatgtaatct aaaaaaaaaa aaaaaaaaaa  1848

```

```

<210> 4
<211> 1028
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (999)..(999)
<223> "n" is A, C, G, or T

```

<400> 4
 acccgcgcac gagccggtgc catctgtggg ggctttgggc caggggtctc cggacagcat 60
 gagcgtgggc ttcacggcg ctggccagct ggcttttgcc ctggccaagg gcttcacagc 120
 agcaggcgtc ttggctgccc acaagataat ggctagctcc ccagacatgg acctggccac 180
 agtttctgct ctcaggaaga tgggggtgaa gttgacaccc cacaacaagg agacggtgca 240
 gcacagtgat gtgctcttcc tggctgtgaa gccacacatc atccccttca tcctggatga 300
 aataggcgcc gacattgagg acagacacat tgtggtgtcc tgcgcggccg gcgtcaccat 360
 cagctccatt gagaagaagc tgtcagcgtt tcggccagcc cccaggggtca tccgctgcat 420
 gaccaacact ccagtcgtgg tgcgggaggg ggccaccgtg tatgccacag gcacgcacgc 480
 ccaggtggag gacgggaggg tcatggagca gctgctgagc agcgtgggct tctgcacgga 540
 ggtggaagag gacctgattg atgccgtcac ggggctcagt ggcagcggcc ccgcctacgc 600
 attcacagcc ctggatgccc tggctgatgg ggggtgtgaag atgggacttc caaggcgcct 660
 ggcagtccgc ctcggggccc aggccctcct gggggctgcc aagatgctgc tgcactcaga 720
 acagcaccca ggccagctca aggacaacgt cagctctcct ggtgggggca ccatccatgc 780
 cttgcatgtg ctggagaagt gggggcttcc gctccctgct catcaacgct gtggaaggcc 840
 tcctgcatcc gcacaccggg agctgcagtc ccatggcctg accaagaagc aggtgttcac 900
 cagccggcat ccagaagaac atccctggga caagggtgaa actgggactc cccctgcaag 960
 gggaccggct cctgtcgcc ttcgggcccc caaccaagnc tggcttcccc cgccagaccg 1020
 tgggcccc 1028

<210> 5
 <211> 1715
 <212> DNA
 <213> Homo sapiens

<400> 5
 agtcatttct tctgcggaac ctccaccctt ccagtgggtg cgggacccta ggcagcaggc 60
 caggcacgc cgctctgact gggggccccg aagcagttaa cgggcccggc agcaaagtgg 120
 aaagttagac cagctgggac caggggaggt gggcaccggt ctgcgggagg agcggccagg 180
 ctggcactgc ccccctaact tgctctcgat cctgccggtc tcgtcccga gagccggtgc 240
 catctgtggg ggctttgggc caggggtctc cggacagcat gagcgtgggc ttcacggcg 300
 ctggccagct ggcttttgcc ctggccaagg ctttcacagc agcaggcgct ttggtgccc 360
 acaagataat ggctagctcc ccagacatgg acctggccac agtttctgct ctcaggaaga 420
 tgggggtgaa gttgacaccc cacaacaagg agacggtgca gcacagtgat gtgctcttcc 480

tggctgtgaa gccacacatc atcccccttca tcctggatga aataggcgcc gacattgagg 540
 acagacacat tgtggtgtcc tgcgcgcccg gcgtcaccat cagctccatt gagaagaagc 600
 tgtcagcgtt tcggccagcc cccaggggtca tccgctgcat gaccaacact ccagtcgtgg 660
 tgcgggaggg ggccaccgtg tatgccacag gacgcacgcc caggtggagg acgggagggt 720
 catggagcag ctgctgagca gcgtgggctt ctgcacggag gtggaagagg acctgattga 780
 tgccgtcacg gggctcagtg gcagcgggccc cgcctacgca ttcacagccc tggatgccct 840
 ggctgatggg ggtgtgaaga tgggacttcc aaggcgcttg gcagtccgcc tcggggccca 900
 ggccctcctg ggggctgcca agatgctgct gcactcagaa cagcaccag gccagctcaa 960
 ggacaacgtc agctctcctg gtggggccac catccatgcc ttgcatgtgc tggagagtgg 1020
 gggcttccgc tcctgtctca tcaacgctgt ggaggcctcc tgcattccgca cacgggagct 1080
 gcagtccatg gctgaccagg agcagggtgc accagccgcc atcaagaaga ccatcctgga 1140
 caaggaccac cttcctctag agctcgggag cccggagggt cttcaccac tcctactcca 1200
 gtatcagctg gcacgggctc cttcctgaga gcaaaggta aggacccct ctgtgaaggc 1260
 tcagcagagg tgggatccca cgcctcctcc cggccctcc ctgccctcca ttcagggaga 1320
 aacctctcct tcccggtgtga gaaggggccag aggggtccagg catcccaagt ccagcgtgaa 1380
 gggccacagc ccctcttggc tgccaagcac gcagatccca tggacatttg gggaaagggc 1440
 tccttgggct gctggtgaac ttctgtggcc accacctcct gctcctgacc tccctgggag 1500
 ggtgctatca gttctgtcct ggccctttca gttttataag ttggtttcca gccccagtg 1560
 tcctgacttc tgtctgccac atgaggaggg aggcctgcc tgtgtgggag ggtggttact 1620
 gtgggtggaa tagtggaggc cttcaactga ttagacaagg cccgcccaca tcttggaggg 1680
 catctgcctt actgattaaa atgtcaatgt aatct 1715

<210> 6
 <211> 860
 <212> DNA
 <213> Homo sapiens

<400> 6
 ggcgtccgag gcaacaagat ggcagctgcg gagccgtctc cgcggcgctt gggcttcgtg 60
 ggcgcgggcc gcatggcggg ggccatcgcg cagggcctca tcagagcagg aaaagtggaa 120
 gctcagcaca tactggccag tgcaccaaca gacaggaacc tatgtcactt tcaagctctg 180
 ggttgccgga ccacgcactc caaccaggag gtgctgcaga gctgcctgct cgtcatcttt 240
 gccaccaagc ctcatgtgct gccagctgtc ctggcagagg tggctcctgt ggtcaccact 300
 gaacacatct tgggtgtccgt ggctgctggg gtgtctctga gcacctgga ggagctgctg 360
 cccccaaca cacgggtgct gcgggtcttg cccaacctgc cctgtgtggt ccaggaaggg 420

gccatagtgga tggcgcgggg ccgccacgtg gggagcagcg agaccaagct cctgcagcat 480
 ctgctggagg cctgtgggag gtgtgaggag gtgcctgaag cctacgtcga catccacact 540
 ggcctcagtg gcagtggcgt ggccttcgtg tgtgcattct ccgaggccct ggctgaagga 600
 gccgtcaaga tgggcatgcc cagcagcctg gccaccgca tcgctgcca gaccctgctg 660
 gggacggcca agatgctgct gcacgagggc caacaccag cccagctgcg ctcagacgtg 720
 tgcaccccg gtggcaccac catctatgga ctccacgccc tggagcaggg cgggctgcga 780
 gcagccacca tgagcgccgt ggaggctgcc acctgccggg ccaaggagct cagcagaaag 840
 taggctgggc tctggccatc 860

<210> 7
 <211> 1178
 <212> DNA
 <213> Homo sapiens

<400> 7
 cggcctgtgg atggcggtg agcgagcgg cgtccgaggc aacaagatgg cagctgcgga 60
 gccgtctccg cggcgcggtg gcttcgtggg cgcgggccgc atggcgggg ccatcgcgca 120
 gggcctcatc agagcaggaa aagtggaagc tcagcacata ctggccagtg caccaacaga 180
 caggaacctc tgtcacttcc aagctctggg ttgccggacc acgcactcca accaggaggt 240
 gctgcagagc tgcctgctcg tcacttttgc caccaagcct catgtgctgc cagctgtcct 300
 ggcagagggtg gctcctgtgg tcaccactga acacatcttg gtgtccgtgg ctgctggggg 360
 gtctctgagc accctggagg agctgctgcc cccaaacaca cgggtgctgc gggctcttgc 420
 caacctgccc tgtgtggtcc aggaaggggc catagtgatg gcgcggggcc gccacgtggg 480
 gagcagcgag accaacctcc tgcagcatct gctggaggcc tgtggcggt gtgaggaggt 540
 gcctgaagcc tacgtcgaca tccacactgg cctcagtggc agtggcgtgg ccttcgtgtg 600
 tgcattctcc gaggccctgg ctgaaggagc cgtcaagatg ggcattgcca gcagcctggc 660
 ccaccgcatc gctgcccaga cctgctggg gacggccaag atgctgctgc acgagggcca 720
 acaccagcc cagctgcgct cagacgtgtg caccggggg ggcaccacca tctatggact 780
 ccacgcctg gagcagggcg ggctgcgagc agccaccatg agcgccgtgg aggtgccac 840
 ctgccggggc aaggagctca gcagaaagta ggctgggctc tggccatcct ttcctgcctc 900
 tgtgcccctg cctctccctg tgtcccttcc cctgaggact gcggctccct ccctcctgca 960
 tgagggtctc ctactgtcc ttctccctt gcacagggaa atgcaggggg caggacttgg 1020
 gaggttccag caggcggggg agccccgacc agtggggaca ctctccctc cccagtggag 1080
 agaaggcacc gtgggtgggtg ctctgcccct tgetgcagtg agcccacctt gctgcaacat 1140

tggttctgag gggcccaaga aaaaaaaaaa aaaaaaaaaa 1178

<210> 8

<211> 1708

<212> DNA

<213> Homo sapiens

<400> 8

gaatagggtt gcaccatccc agaagctgct gttagctcgc cggtcctcgg cagccgccc	60
gttcgccctt gcgctgtccg cccttcccct agcgttactt ccggtccctc gctgaggggg	120
ttcgtgcggc tcccaggagg cgtgaaccgc ggaccatgag cgtgggcttc atcggggccg	180
gccagctggc ctatgctctg gcgcggggct tcacggccgc aggcattcctg tcggctcaca	240
agataatagc cagctcccca gaaatgaacc tgcccacggt gtccgcgctc aggaagatgg	300
gtgtgaacct gacacgcagc aacaaggaga cggatgaagc cagcgacgct ctgtttctgg	360
ctgtgaagcc acatatcctc cccttccatc tggatgagat tggggccgac gtgcaagcca	420
gacacatcgt ggtctcctgt gcggctgggt tcaccatcag ctctgtggag aagaagctga	480
tggcattcca gccagcccc aaagtgattc gctgcatgac caacacacct gtggtagtgc	540
aggaaggcgc tacagtgtac gccacgggca cccatgccct ggtggaggat gggcagctcc	600
tggagcagct catgagcagc gtgggcttct gcactgaggt ggaagaggac ctcatcgatg	660
ccgtcacggg gctcagtggc agcgggcctg cctatgcatt catggctctg gacgcattgg	720
ctgatggtgg ggtgaagatg gggttgccac ggcgcctggc aatccaactc ggggcccagg	780
ctttgctggg agctgccaag atgctgctgg actcggagca gcatccatgc cagcttaagg	840
acaatgtctg ctcccctggg ggagccacca tccacgccct gcactttcta gagagtgggg	900
gcttccgctc tctgctcctc aatgcagttg aggcctcctg tatccgaaca cgagagctac	960
agtccatggc cgaccaagaa aagatctccc cagctgccct taagaagacc ctcttagaca	1020
gagtgaagct ggaatcccc acagtctcca cactgacccc ctccagccca gggaagctcc	1080
tcacaagaag cctggccctg ggaggcaaga aggactaagg cagcatctgt cccctctgtg	1140
attcagagcc cttagttagg agcccctgcc gcccctgcca ccccctgcc ccgctcccac	1200
cattgccctt cctcagctgt gcaaggagaa agcatgctta ggaagtcttc aggtccttgt	1260
gataaaacct ccttaaatct gttcagacca agcaatgcga gcttctcttc ctgtcccatg	1320
ttggaagttg ctctgaaggg gtggttagatg ctggaagcca gacacaacct tgcgtacgct	1380
gctcagttgg tggagactgg ggctgggact ggagtcagcc cagctgggag gaggggctgg	1440
ggaggatctg cagctgaagc ccgaggcagg gttggtgtga tgccaaggca aagtggtagg	1500
gagaaaacag gaaacgggct ttctctgaat tggtaaatgg gaaagaagtg agcaacttaa	1560
gattgtcaca attaatcaca agtgtacagg attagactgg gtttatatct aactcttgct	1620

tcataggtgt accatTTaaa gagtgTtatt taatgctaag tTTaactgct ttaataaagt 1680
 ttatTTTTTaa ataaaaaaaa aaaaaaaaa 1708

<210> 9
 <211> 999
 <212> DNA
 <213> Homo sapiens

<400> 9
 gcggctccca ggaggcgtga accgcggacc atgagcgtgg gcttcatcgg ggccggccag 60
 ctggctatgc tctggcgagg ggcttcacgg ccgcagattc ctgtcggctc acaagataat 120
 agccagctcc ccagaaatga acctgcccac ggtgtccgag ctgaggaaga tgggtgtgaa 180
 cctgacacgc agcaacaagg agacgggtgaa gcacagcgac gtctgttttc tggctgtgaa 240
 gcacatatca tccccttcat cctgggttag attggggccg acgtgcaagc cagacacatc 300
 gtggtctcct gtgcggctgg tgttaccatc agctctgtgg agaagaagct gatggaattc 360
 cagccagccc ccaaagtgat tcgctgcatg accaacacac ctgtggtagt gcaggaagggc 420
 gctacagtgt acgccacggg caccatgcc ctggtggagg atgggcagct cctggagcag 480
 ctcatgagca gcgtgggctt ctgcactgag gtggaagagg acctcatcga tgccgtcacg 540
 gggctcagtg gcagcaaacc tgcctatgca ttcattggctc tggacgcatt ggctgatggg 600
 ggggtgaaga tgggtttgcc acggcgccctg gcaatccaac tcggggccca ggctttgctg 660
 ggagctgcca agatgctgct ggactcggag cagcatccat gccagcttaa ggacaatgtc 720
 tgctcccttg ggggagccac catccacgcc ctgcactttc tagagagtgg gggcttccgc 780
 tctctgctca tcaatgcagt tgaggcctcc tgtatccgaa cagagagct acagtccatg 840
 gccgaccaag aaaagatctc ccagctgcc cttaagaaga ccctcttaga cagagtgaag 900
 ctggaatccc ccacagtctc cacttgacc ccctccagcc cagggaagct ctcacaaga 960
 agcctggccc tgggaggcaa gaaggactaa ggcagcatc 999

<210> 10
 <211> 319
 <212> PRT
 <213> Homo sapiens

<400> 10

Met Ser Val Gly Phe Ile Gly Ala Gly Gln Leu Ala Phe Ala Leu Ala
 1 5 10 15

Lys Gly Phe Thr Ala Ala Gly Val Leu Ala Ala His Lys Ile Met Ala
 20 25 30

Ser Ser Pro Asp Met Asp Leu Ala Thr Val Ser Ala Leu Arg Lys Met
 35 40 45

Gly Val Lys Leu Thr Pro His Asn Lys Glu Thr Val Gln His Ser Asp
 50 55 60

Val Leu Phe Leu Ala Val Lys Pro His Ile Ile Pro Phe Ile Leu Asp
 65 70 75 80

Glu Ile Gly Ala Asp Ile Glu Asp Arg His Ile Val Val Ser Cys Ala
 85 90 95

Ala Gly Val Thr Ile Ser Ser Ile Glu Lys Lys Leu Ser Ala Phe Arg
 100 105 110

Pro Ala Pro Arg Val Ile Arg Cys Met Thr Asn Thr Pro Val Val Val
 115 120 125

Arg Glu Gly Ala Thr Val Tyr Ala Thr Gly Thr His Ala Gln Val Glu
 130 135 140

Asp Gly Arg Leu Met Glu Gln Leu Leu Ser Thr Val Gly Phe Cys Thr
 145 150 155 160

Glu Val Glu Glu Asp Leu Ile Asp Ala Val Thr Gly Leu Ser Gly Ser
 165 170 175

Gly Pro Ala Tyr Ala Phe Thr Ala Leu Asp Ala Leu Ala Asp Gly Gly
 180 185 190

Val Lys Met Gly Leu Pro Arg Arg Leu Ala Val Arg Leu Gly Ala Gln
 195 200 205

Ala Leu Leu Gly Ala Ala Lys Met Leu Leu His Ser Glu Gln His Pro
 210 215 220

Gly Gln Leu Lys Asp Asn Val Ser Ser Pro Gly Gly Ala Thr Ile His
 225 230 235 240

Ala Leu His Val Leu Glu Ser Gly Gly Phe Arg Ser Leu Leu Ile Asn
 245 250 255

Ala Val Glu Ala Ser Cys Ile Arg Thr Arg Glu Leu Gln Ser Met Ala
 260 265 270

Asp Gln Glu Gln Val Ser Pro Ala Ala Ile Lys Lys Thr Ile Leu Asp
 275 280 285

Lys Val Lys Leu Asp Ser Pro Ala Gly Thr Ala Leu Ser Pro Ser Gly
 290 295 300

His Thr Lys Leu Leu Pro Arg Ser Leu Ala Pro Ala Gly Lys Asp
 305 310 315

<210> 11
 <211> 274
 <212> PRT
 <213> Homo sapiens

<400> 11

Met Ala Ala Ala Glu Pro Ser Pro Arg Arg Val Gly Phe Val Gly Ala
 1 5 10 15

Gly Arg Met Ala Gly Ala Ile Ala Gln Gly Leu Ile Arg Ala Gly Lys
 20 25 30

Val Glu Ala Gln His Ile Leu Ala Ser Ala Pro Thr Asp Arg Asn Leu
 35 40 45

Cys His Phe Gln Ala Leu Gly Cys Arg Thr Thr His Ser Asn Gln Glu
 50 55 60

Val Leu Gln Ser Cys Leu Leu Val Ile Phe Ala Thr Lys Pro His Val
 65 70 75 80

Leu Pro Ala Val Leu Ala Glu Val Ala Pro Val Val Thr Thr Glu His
 85 90 95

Ile Leu Val Ser Val Ala Ala Gly Val Ser Leu Ser Thr Leu Glu Glu
 100 105 110

Leu Leu Pro Pro Asn Thr Arg Val Leu Arg Val Leu Pro Asn Leu Pro
 115 120 125

Cys Val Val Gln Glu Gly Ala Ile Val Met Ala Arg Gly Arg His Val
 130 135 140

Gly Ser Ser Glu Thr Lys Leu Leu Gln His Leu Leu Glu Ala Cys Gly
 145 150 155 160

Arg Cys Glu Glu Val Pro Glu Ala Tyr Val Asp Ile His Thr Gly Leu
 165 170 175

Ser Gly Ser Gly Val Ala Phe Val Cys Ala Phe Ser Glu Ala Leu Ala

180 185 190
 Glu Gly Ala Val Lys Met Gly Met Pro Ser Ser Leu Ala His Arg Ile
 195 200 205
 Ala Ala Gln Thr Leu Leu Gly Thr Ala Lys Met Leu Leu His Glu Gly
 210 215 220
 Gln His Pro Ala Gln Leu Arg Ser Asp Val Cys Thr Pro Gly Gly Thr
 225 230 235 240
 Thr Ile Tyr Gly Leu His Ala Leu Glu Gln Gly Gly Leu Arg Ala Ala
 245 250 255
 Thr Met Ser Ala Val Glu Ala Ala Thr Cys Arg Ala Lys Glu Leu Ser
 260 265 270

Arg Lys

<210> 12
 <211> 319
 <212> PRT
 <213> Homo sapiens

<400> 12

Met Ser Val Gly Phe Ile Gly Ala Gly Gln Leu Ala Phe Ala Leu Ala
 1 5 10 15

Lys Gly Phe Thr Ala Ala Gly Val Leu Ala Ala His Lys Ile Met Ala
 20 25 30

Ser Ser Pro Asp Met Asp Leu Ala Thr Val Ser Ala Leu Arg Lys Met
 35 40 45

Gly Val Lys Leu Thr Pro His Asn Lys Glu Thr Val Gln His Ser Asp
 50 55 60

Val Leu Phe Leu Ala Val Lys Pro His Ile Ile Pro Phe Ile Leu Asp
 65 70 75 80

Glu Ile Gly Ala Asp Ile Glu Asp Arg His Ile Val Val Ser Cys Ala
 85 90 95

Ala Gly Val Thr Ile Ser Ser Ile Glu Lys Lys Leu Ser Ala Phe Arg
 100 105 110

Pro Ala Pro Arg Val Ile Arg Cys Met Thr Asn Thr Pro Val Val Val
 115 120 125

Arg Glu Gly Ala Thr Val Tyr Ala Thr Gly Thr His Ala Gln Val Glu
 130 135 140

Asp Gly Arg Leu Met Glu Gln Leu Leu Ser Thr Val Gly Phe Cys Thr
 145 150 155 160

Glu Val Glu Glu Asp Leu Ile Asp Ala Val Thr Gly Leu Ser Gly Ser
 165 170 175

Gly Pro Ala Tyr Ala Phe Thr Ala Leu Asp Ala Leu Ala Asp Gly Gly
 180 185 190

Val Lys Met Gly Leu Pro Arg Arg Leu Ala Val Arg Leu Gly Ala Gln
 195 200 205

Ala Leu Leu Gly Ala Ala Lys Met Leu Leu His Ser Glu Gln His Pro
 210 215 220

Gly Gln Leu Lys Asp Asn Val Ser Ser Pro Gly Gly Ala Thr Ile His
 225 230 235 240

Ala Leu His Val Leu Glu Ser Gly Gly Phe Arg Ser Leu Leu Ile Asn
 245 250 255

Ala Val Glu Ala Ser Cys Ile Arg Thr Arg Glu Leu Gln Ser Met Ala
 260 265 270

Asp Gln Glu Gln Val Ser Pro Ala Ala Ile Lys Lys Thr Ile Leu Asp
 275 280 285

Lys Val Lys Leu Asp Ser Pro Ala Gly Thr Ala Leu Ser Pro Ser Gly
 290 295 300

His Thr Lys Leu Leu Pro Arg Ser Leu Ala Pro Ala Gly Lys Asp
 305 310 315

<210> 13
 <211> 274
 <212> PRT
 <213> Homo sapiens

<400> 13

Met Ala Ala Ala Glu Pro Ser Pro Arg Arg Val Gly Phe Val Gly Ala
 1 5 10 15

Gly Arg Met Ala Gly Ala Ile Ala Gln Gly Leu Ile Arg Ala Gly Lys
 20 25 30
 Val Glu Ala Gln His Ile Leu Ala Ser Ala Pro Thr Asp Arg Asn Leu
 35 40 45
 Cys His Phe Gln Ala Leu Gly Cys Arg Thr Thr His Ser Asn Gln Glu
 50 55 60
 Val Leu Gln Ser Cys Leu Leu Val Ile Phe Ala Thr Lys Pro His Val
 65 70 75 80
 Leu Pro Ala Val Leu Ala Glu Val Ala Pro Val Val Thr Thr Glu His
 85 90 95
 Ile Leu Val Ser Val Ala Ala Gly Val Ser Leu Ser Thr Leu Glu Glu
 100 105 110
 Leu Leu Pro Pro Asn Thr Arg Val Leu Arg Val Leu Pro Asn Leu Pro
 115 120 125
 Cys Val Val Gln Glu Gly Ala Ile Val Met Ala Arg Gly Arg His Val
 130 135 140
 Gly Ser Ser Glu Thr Lys Leu Leu Gln His Leu Leu Glu Ala Cys Gly
 145 150 155 160
 Arg Cys Glu Glu Val Pro Glu Ala Tyr Val Asp Ile His Thr Gly Leu
 165 170 175
 Ser Gly Ser Gly Val Ala Phe Val Cys Ala Phe Ser Glu Ala Leu Ala
 180 185 190
 Glu Gly Ala Val Lys Met Gly Met Pro Ser Ser Leu Ala His Arg Ile
 195 200 205
 Ala Ala Gln Thr Leu Leu Gly Thr Ala Lys Met Leu Leu His Glu Gly
 210 215 220
 Gln His Pro Ala Gln Leu Arg Ser Asp Val Cys Thr Pro Gly Gly Thr
 225 230 235 240
 Thr Ile Tyr Gly Leu His Ala Leu Glu Gln Gly Gly Leu Arg Ala Ala
 245 250 255
 Thr Met Ser Ala Val Glu Ala Ala Thr Cys Arg Ala Lys Glu Leu Ser

260

265

270

Arg Lys

<210> 14

<211> 319

<212> PRT

<213> Homo sapiens

<400> 14

Met Ser Val Gly Phe Ile Gly Ala Gly Gln Leu Ala Met Leu Trp Arg
 1 5 10 15

Gly Ala Ser Arg Pro Gln Ile Pro Val Gly Ser Gln Asp Asn Ser Gln
 20 25 30

Leu Pro Arg Asn Glu Pro Ala His Gly Val Arg Ala Gln Glu Asp Gly
 35 40 45

Cys Glu Pro Asp Thr Gln Gln Gln Gly Asp Gly Glu Ala Gln Arg Arg
 50 55 60

Pro Val Ser Gly Cys Glu Ala His Ile Ile Pro Phe Ile Leu Val Glu
 65 70 75 80

Ile Gly Ala Asp Val Gln Ala Arg His Ile Val Val Ser Cys Ala Ala
 85 90 95

Gly Val Thr Ile Ser Ser Val Glu Lys Lys Leu Met Glu Phe Gln Pro
 100 105 110

Ala Pro Lys Val Ile Arg Cys Met Thr Asn Thr Pro Val Val Val Gln
 115 120 125

Glu Gly Ala Thr Val Tyr Ala Thr Gly Thr His Ala Leu Val Glu Asp
 130 135 140

Gly Gln Leu Leu Glu Gln Leu Met Ser Ser Val Gly Phe Cys Thr Glu
 145 150 155 160

Val Glu Glu Asp Leu Ile Asp Ala Val Thr Gly Leu Ser Gly Ser Lys
 165 170 175

Pro Ala Tyr Ala Phe Met Ala Leu Asp Ala Leu Ala Asp Gly Gly Val
 180 185 190

Lys Met Gly Leu Pro Arg Arg Leu Ala Ile Gln Leu Gly Ala Gln Ala
195 200 205

Leu Leu Gly Ala Ala Lys Met Leu Leu Asp Ser Glu Gln His Pro Cys
210 215 220

Gln Leu Lys Asp Asn Val Cys Ser Pro Gly Gly Ala Thr Ile His Ala
225 230 235 240

Leu His Phe Leu Glu Ser Gly Gly Phe Arg Ser Leu Leu Ile Asn Ala
245 250 255

Val Glu Ala Ser Cys Ile Arg Thr Arg Glu Leu Gln Ser Met Ala Asp
260 265 270

Gln Glu Lys Ile Ser Pro Ala Ala Leu Lys Lys Thr Leu Leu Asp Arg
275 280 285

Val Lys Leu Glu Ser Pro Thr Val Ser Thr Leu Thr Pro Ser Ser Pro
290 295 300

Gly Lys Leu Leu Thr Arg Ser Leu Ala Leu Gly Gly Lys Lys Asp
305 310 315